**Friedrich et al**

**Supplemental Digital Content**

**Page number**

**Supplemental Methods 2**

**Supplemental Figure 1 5**

**Supplemental Figure 2 6**

**Supplemental Figure 3 7**

**Supplemental Figure 4 8**

**Supplemental Figure 5 9**

**Supplemental Table 1 10**

**Supplemental Table 2 57**

**Supplemental Methods**

***Search Strategy***

We surveyed fifteen leading journals for RCTs recruiting patients admitted to an ICU and published since 1990. The MeSH terms brain injuries/, craniocerebral trauma critical care/, critical illness/, intensive care/, intensive care units/, ventilators, mechanical/, systematic respiratory distress syndrome/ acute respiratory distress syndrome/ and acute lung injury/ were all searched in Medline, and limited these journals: *New England Journal of Medicine*, *JAMA*, *Lancet*, *Annals of Internal Medicine*, *British Medical Journal*, *American Journal of Respiratory and Critical Care Medicine*, *Critical Care Medicine,* *Intensive Care Medicine*, *Chest*, *Critical Care*, *Journal of Critical Care*, *Shock,* *Journal of Trauma, Infection, and Critical Care*, *Pediatric Critical Medicine*, and *Journal of Pediatrics*.

Database: Ovid MEDLINE(R) <1946 to August Week 2 2019>

Search Strategy:

--------------------------------------------------------------------------------

1 (exp brain injuries/ or exp craniocerebral trauma/ or neurotrauma.mp.) and (icu or critical or intensive).mp. (8143)

2 (critical adj1 (care or ill$)).mp. (84083)

3 exp ventilators, mechanical/ or (non-invasive adj1 ventilat$).mp. or artificial respiration/ (54712)

4 exp systemic inflammatory response syndrome/ or exp sepsis/ (121301)

5 exp shock, septic/ (21665)

6 exp respiratory distress syndrome, adult/ or ARDS.mp. (20946)

7 exp acute lung injury/ (5767)

8 exp critical care/ or exp critical illness/ (75783)

9 exp intensive care/ or exp intensive care unit/ (121858)

10 or/1-9 (319509)

11 \*burns/ or \*coronary care units/ (39073)

12 10 not 11 (313203)

13 "new england journal of medicine".jn. (77747)

14 jama.jn. (71184)

15 lancet.jn. (135297)

16 "annals of internal medicine".jn. (31448)

17 bmj.jn. (70206)

18 "american journal of respiratory & critical care medicine".jn. (14345)

19 critical care medicine.jn. (19970)

20 intensive care medicine.jn. (10292)

21 chest.jn. (33153)

22 critical care london england.jn. (6430)

23 "journal of critical care".jn. (3034)

24 shock.jn. (4481)

25 "journal of trauma injury infection & critical care".jn. (15399)

26 "journal of pediatrics".jn. (30970)

27 pediatric critical care medicine.jn. (3514)

28 12 and (or/13-27) (46012)

29 limit 28 to yr="1990 - 2018" (40733)

30 limit 29 to randomized controlled trial (2592)

***Calculation of Incremental Risk Differences***

For each trial, we calculated incremental risk differences [RD] as the incremental mortality risk between successive time points 1 and 2 in experimental group A (the group with the higher mortality) minus the incremental mortality risk in experimental group B (the group with the lower mortality):

Incremental RD =

Where D2A and D2B are the cumulative number of deaths at the second time point, D1A and D1B are the cumulative number of deaths at the first time point, and NA and Ni are the total numbers of patients randomized to study groups A and B. The numerators are the number of additional deaths that occurred between the two time points in each randomized group, while the denominators reflect the number of patients alive at the earlier time point (i.e. those still alive at the earlier time point 1).

For example, assume a trial of having 100 subjects randomized to one of two study groups- A and B - at baseline (T0). If by time point 1 (T1) 5 patients in group A and 6 patients in group B had died, and that by the more remote time point 2 (T2) a total of 9 patients in Group A and 8 patients in Group B had died, then the incremental mortality risk between time point 2 and time point 1 would be calculated as (9-5)/(100-5)=4/95 in the first group vs. (8-6)/(100-6)=2/94 in the second group [the denominators of 95 in the intervention group vs. n=94 in the control group representing the living patients at time point 1 who are still at risk between time points 1 and 2], and the incremental risk difference (RD) would be calculated as the difference of these two fractions, 2/94 - 4/95.

C:\Users\marshallj\Downloads\Supplemental Firgure 1 (1).tif

C:\Users\marshallj\Downloads\Supplemental Figure 2.tif

C:\Users\marshallj\Downloads\Supplemental Figure 3.tif

C:\Users\marshallj\Downloads\Supplemental Figure 4.tif

C:\Users\marshallj\Downloads\Supplemental Figure 5.tif

**Supplemental Table 1: RCTs Included in Systematic Review**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author Year | Intervention | EnrolYear | Harm | %US | ICU | Hosp | 7d | 14d | 28/  30d | 60d | 90d | 180  d | ≥1y | Min  p |
| *Non-Sepsis/SIRS, Non-ALI/ARDS* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Gutierrez 1992 | Gastric tonometry | 1990 |  | 0%-Arg | **Y** | Y | Y | Y | Y |  |  |  |  | <0.05 |
| GBS Steroid Trial Group 1990 | Steroids (GBS) | 1989 | Y | 0% |  |  | Y | Y | Y | **Y** | **Y** | **Y** | Y-48 wks | <0.2 |
| Hammond 1992 | Selective Digest.Decontam. | 1990 |  | 0%-SAfr | Y | Y |  |  |  |  |  |  |  |  |
| Korinek 1993 | Selective Digest.Decontam. | 1990 |  | 0% | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Ben-Menachem 1994\* | Sucraflate/cimetidine | 1992 |  | 100% | Y | Y |  |  |  |  |  |  |  |  |
| Hayes 1994 | High oxygen | n/r | Y | 0% | **Y** | **Y** | Y | Y | Y |  |  |  |  | <0.05 |
| Gattionni 1995\* | High oxygen/cardiac index | 1992 |  | 0% | Y |  | Y | Y | Y | Y | Y | Y |  |  |
| Atkinson 1998 | Immunonutrition | 1993 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Corwin 1999 | Erythropoietin | 1995 |  | 100% |  |  | Y | Y | Y |  |  |  |  |  |
| Esteban 1999 | 120 v 30 min SBT0 | 1996 |  | 0% | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Hébert/TRICC 1999 | Restrictive transfusion | 1996 |  | 0% | Y | **Y** | Y | Y | **Y** | Y |  |  |  | <0.2 |
| Holzapfel 1999 | Sinusitis Eval. (Nasal Intub.) | n/r |  | 0% |  |  | Y | **Y** | **Y** | **Y** |  |  |  | <0.05 |
| Takala 1999 | Growth hormone (Finland) | 1995 | Y | 0% | **Y** | **Y** | **Y** | **Y** | **Y** |  |  | **Y** |  | <0.05 |
| Takala 1999 | Growth hormone (Europe) | 1995 | Y | 0% | **Y** | **Y** | **Y** | **Y** | **Y** |  |  | **Y** |  | <0.05 |
| Bauer 2000 | Supp. parenteral nutrition | 1997 |  | 0% |  |  | Y | Y | Y | Y | Y |  | Y-2y |  |
| Fagon 2000 | BAL v ETT sputum culture | 1997 |  | 0% |  |  | Y | **Y** | Y |  |  |  |  | <0.05 |
| Gomersall 2000 | Gastric tonometry | 1996 |  | 0%-HK | Y | Y | Y | Y | Y |  |  |  |  |  |
| Herr 2000 | Propofol±EDTA | 1995 |  | 100% |  |  | **Y** |  | **Y** |  |  |  |  | <0.05 |
| Higgins 2000 | Propofol+EDTA v other sed. | n/r |  | 100% |  |  | Y |  | Y |  |  |  |  |  |
| Bergmans 2001^ | Selective Digest.Decontam. | 1995 |  | 0% | **Y** | Y |  |  | Y | Y | Y | Y | Y | <0.2 |
| Stiell 2001 | Epi v Vaso (cardiac arrest) | 1998 |  | 0% |  | Y |  |  | Y |  |  |  |  |  |
| Van den Berghe 2001 | Intensive insulin therapy | 2000 |  | 0% | **Y** | **Y** |  |  |  |  |  |  |  | <0.05 |
| Corwin 2002 | Erythropoietin | 2000 |  | 100% |  |  | Y | Y | Y |  |  |  |  |  |
| Krueger 2002 | Select IV&Digest.Decontam | n/r |  | 0% | **Y** |  | Y | Y | Y | Y |  |  | Y | <0.05 |
| Ralph 2002 | Dopexamine | n/r |  | 0% | Y | Y | Y |  |  |  |  |  |  |  |
| de Jonge 2003 | Select IV&Digest.Decontam | 2000 |  | 0% | **Y** | **Y** | Y | Y | Y | **Y** | **Y** |  |  | <0.05 |
| Hall 2003 | Enteral glutamine | 1998 |  | 0% | Y | Y |  |  | Y |  |  | Y |  |  |
| Sandham 2003 | Pulmonary Artery Catheter | 1994 |  | 0% |  | Y | Y | Y | Y | Y | Y | Y | Y |  |
| Krishnan 2004 | Vent Weaning Protocol | 2000 |  | 100% | Y | Y |  |  |  |  |  |  |  |  |
| Rumback 2004 | Early tracheostomy | n/r |  | 100% |  | **Y** | Y | Y | **Y** |  |  |  |  | <0.05 |
| SAFE 2004 | Albumin | 2002 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Harvey 2005 | Pulmonary Artery Catheter | 2003 |  | 0% | Y | Y | Y | Y | Y | Y1 | Y1 |  |  |  |
| Kieft 2005 | Immunonutrition | 1999 |  | 0% | Y | Y |  |  | Y |  |  |  |  |  |
| Pearse 2005 | Early Goal DirectedTherapy | 2003 |  | 0% |  |  |  |  | Y | Y |  |  |  |  |
| Boots 2006 | HME v HW humidification | n/r |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| CCCTG/VAP 2006 | BAL v ETT sputum culture | 2002 |  | <10% | Y | Y |  | Y | Y |  |  |  |  |  |
| Ferrer 2006 | NIV post extubation | 2002 |  | 0% | **Y** | Y | Y | Y | Y | Y | Y |  |  | <0.05 |
| Kollef/POPS-1 2006 | Iseganan-antimicr peptide | 2004 | Y | 10-90% |  |  | **Y** | **Y** |  |  |  |  |  | <0.2 |
| Lellouche 2006 | Computer-driven weaning | 2003 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Sylvester 2006 | Surg v percutaneous trach | 1999 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Thwaites 2006 | Magnesium (for tetanus) | 2003 |  | 0%-Viet |  | Y | Y | Y | Y |  |  |  |  |  |
| Van den Berghe 2006 | Intensive insulin therapy | 2003 |  | 0% | Y | Y |  |  | Y |  | Y |  |  |  |
| Vinsonneau 2006 | Contin v intermit dialysis | 2001 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| von Nieuwenhoven 2006 | Semirecumbent position | 2000 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Chytra 2007 | Esoph Doppler Guided IVF | 2004 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Corwin 2007 | Erythropoietin | 2005 |  | 100% |  |  | Y | Y | **Y** |  |  | **Y**-140d |  | <0.2 |
| Pandharipande/MENDS 2007 | Dexmedetomidine v loraz. | 2005 |  | 100% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Templeton 2007 | Chest physiotherapy | 1998 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Valencia 2007 | Contin. auto. cuff pressure | 2004 | Y | 0% | Y | Y | **Y** | **Y** | Y | Y | Y |  |  | <0.2 |
| Arabi 2008 | Intensive insulin therapy | 2005 |  | 0%-KSA | Y | Y | Y2 | Y2 | **Y** 2 |  |  |  |  | <0.05 |
| Berger 2008 | IV antioxidants | 2003 |  | 0% | Y | Y |  |  |  |  | Y |  |  |  |
| Blot 2008 | Early tracheostomy | 2003 |  | 0% |  |  | Y | Y | Y | Y |  |  |  |  |
| Bucknall 2008 | Protocolized sedation | n/r |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Clec’h 2008 | No daily routine CXR | 2006 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| De La Rosa 2008 | Intensive insulin therapy | 2004 |  | 0%-Col | Y | Y |  |  | Y |  |  |  |  |  |
| Desachy 2008 | Immed. v gradual feeding | n/r |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Girard/ABC 2008 | Sedation+weaning protocol | 2005 |  | 100% |  |  | Y | Y | Y | **Y** | **Y** | **Y** | **Y** | <0.05 |
| Gray 2008 | C/BiPAP (for pulm edema) | 2005 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Myburgh/CAT 2008 | Epinephrine v Norepi | 2005 |  | 0% |  |  |  |  | Y |  | Y |  |  |  |
| ATN 2008 | Intensive v standard RRT | 2005 |  | 100% |  | Y | Y | Y | Y | Y |  |  |  |  |
| Xiao 2008 | Progesterone (for TBI) | 2005 |  | 0%-Chi |  | **Y** |  |  |  |  | **Y** | **Y** |  | <0.05 |
| Xirouchaki 2008 | PAV+ vs PSV | 2007 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Ferrer 2009 | NIV post extubation | 2006 |  | 0% | Y | Y | Y | Y | Y | **Y** | **Y** |  |  | <0.05 |
| Jabre/KETASED 2009 | Etomidate v ketamine (for intub) | 2007 |  | 0% |  |  | **Y** | Y | Y |  |  |  |  | <0.2 |
| Knight 2009 | Syn(pre+pro)biotic | 2004 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| NICE-SUGAR 2009 | Intensive insulin therapy | 2006 | Y | 0% | Y | **Y** | Y | Y | Y | **Y** | **Y** |  |  | <0.05 |
| Oudemans 2009 | Citrate v heparin (for CRRT) | 2005 |  | 0% |  | **Y** | Y | Y | **Y** | **Y** | **Y** |  |  | <0.05 |
| Patman 2009 | Respiratory Physiotherapy | 2002 |  | 0% | **Y** |  |  |  |  |  | **Y** |  |  | <0.2 |
| Preiser/Glucontrol2009 | Intensive insulin therapy | 2005 | Y | 0% | Y | **Y** |  |  | **Y** |  |  |  |  | <0.2 |
| RENAL 2009 | Intensive v standard CRRT | 2007 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Riker/SEDCOM 2009 | Dexmedetomidine v midaz. | 2006 |  | >80% | Y |  |  |  | Y |  |  |  |  |  |
| Timsit/Dressing 2009 | 3 v 7d CVC dressing change | 2007 |  | 0% | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Timsit/Dressing 2009 | Chlorhexidine CVC dressing | 2007 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Treggiari 2009 | Light v deep sedation | 2004 |  | 0% | Y | Y |  |  | Y |  |  |  |  |  |
| Barraud 2010 | Probiotics | 2007 |  | 0% | Y |  | Y | Y | Y | Y | Y |  |  |  |
| Hajjar/TRACS 2010 | Liberal transfus (for card surg) | 2009 |  | 0%-Bra |  |  | Y | Y | **Y** |  |  |  |  | <0.2 |
| Lacherade 2010 | Subglottic secretion drain. | 2005 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Maggiore 2010 | Helium-O2 (for COPD Rx NIV) | 2001 |  | 0% | Y | Y |  |  | **Y** |  |  |  |  | <0.2 |
| Montejo/REGANE 2010 | High v low gastric resid. vol. | 2006 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Staudinger 2010 | Continuous lateral rotation | 2007 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Strøm 2010 | No sedation protocol | 2008 |  | 0% | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Terragni 2010 | Early tracheostomy | 2006 |  | 0% |  | Y |  |  | Y |  |  |  | Y |  |
| van Eijk 2010 | Rivastigmine (for delirium) | 2009 | Y | 0% |  |  | Y | **Y** | **Y** | **Y** | **Y** |  |  | <0.2 |
| Andrews/SIGNET 2011 | IV glutamine | 2006 |  | 0% | Y |  | Y | Y | Y | **Y** | Y | Y |  | <0.2 |
| Andrews/SIGNET 2011 | IV selenium | 2006 |  | 0% | Y |  | Y | Y | Y | Y | Y | Y |  |  |
| PROTECT 2011 | LMW v unfraction. heparin | 2008 |  | <10% | Y | **Y** |  |  |  |  |  |  |  | <0.2 |
| Trouillet 2011 | Early trach. (for card. surg.) | 2007 |  | 0% |  |  | Y | Y | Y | Y | Y |  | Y3 |  |
| Caesar/EPaNIC 2011 | Early v late parental nutr. | 2009 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| David 2011 | Closed v open suctioning | 2007 |  | 0%-Ind | Y | Y |  |  |  |  |  |  |  |  |
| Ducros 2011 | CPAP (for pulm edema) | 2006 |  | 0% |  | Y | Y |  |  |  |  |  |  |  |
| Grau 2011 | IV glutamine | 2006 |  | 0% | Y |  |  |  |  |  |  | Y |  |  |
| Hauser/CONTROL 2011 | Act Fac VII (for trauma) | 2007 |  | 10-90% |  |  |  |  | Y |  | Y |  |  |  |
| Makris 2011 | Pravastatin | 2009 |  | 0% | **Y** |  |  |  | **Y** |  |  | Y |  | <0.05 |
| Rice 2011 | Trophic v full energy feeds | 2006 |  | 100% |  | Y | Y | Y | Y |  |  |  |  |  |
| Singer/TICACOS 2011 | Calorimetric-guided feeds | 2007 |  | 0%-Isr | Y | **Y** |  |  |  | Y |  |  |  | <0.2 |
| Takala 2011 | Non-invasive CO monitor | 2007 | Y | 0% | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Chesnut 2012 | ICP monitor (for severe TBI) | 2010 |  | 0%SAm |  |  | Y | **Y** | **Y** | Y | Y | Y |  | <0.2 |
| Kwakman 2012 | Honey (for CVC infxn prev) | 2010 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Mehta/SLEAP 2012 | Sed Protocol±Daily Interupt | 2009 |  | <10% | Y | Y |  |  |  |  |  |  |  |  |
| Mekontso Dessap 2012 | BNP fluid mgmt. (for wean) | 2008 |  | 0% | Y | Y |  |  |  | Y |  |  |  |  |
| Myburgh/CHEST 2012 | 6% HES (130/0.4) v saline | 2011 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Schädler 2012 | Automated Vent Weaning | 2007 |  | 0% |  |  |  |  | Y |  | Y |  |  |  |
| Annane/CRISTAL 2013 | Colloid v crystalloid | 2007 |  | 0% | Y | Y | Y | Y | Y | **Y** | **Y** |  |  | <0.05 |
| Denehy 2013 | Exercise rehabilitaton | 2008 |  | 0% | Y | Y |  |  | Y |  | Y | Y | Y |  |
| Doig 2013 | Early parenteral nutrition | 2009 |  | 0% | **Y** | Y |  |  |  | Y |  |  |  | <0.2 |
| Heiddegger 2013 | Supp parenteral nutrition | 2009 |  | 0% | Y | **Y** |  |  |  |  |  |  |  | <0.2 |
| Hernandez 2013 | Cuff deflation (for trach wean) | 2010 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Heyland/REDOX 2013 | IV glutamine | 2008 | Y | ~10% |  | **Y** | Y | **Y** | **Y** | **Y** | **Y** | **Y** |  | <0.05 |
| Heyland/REDOX 2013 | IV antioxidants | 2008 | Y | ~10% |  | Y | Y | Y | Y | Y | Y | Y |  |  |
| Nielsen/TTM 2013 | Hypothermia (card. arrest) | 2011 | Y | 0% | **Y** | Y | Y | **Y** | Y | Y | Y | Y |  | <0.2 |
| Papazian/STATIN-VAP 2013 | Simvistatin (for susp. VAP) | 2011 | Y | 0% | Y | Y | Y | Y | **Y** |  |  |  |  | <0.2 |
| Reignier/NUTRIREA1 2013 | No gastric. resid. vol. monitoring | 2010 |  | 0% | Y |  |  |  | Y |  | Y |  |  |  |
| Vignon/CIREA I 2013 | Pneum. compr. v stockings | 2009 |  | 0% |  |  | Y-6d |  | Y |  | Y |  |  |  |
| Walsh/RELIEVE 2013 | Restrictive transfusion | 2010 |  | 0% | Y | Y | Y | Y | Y | **Y** | **Y** | **Y** |  | <0.2 |
| Young/TracMan 2013 | Early tracheostomy | 2006 |  | 0% | Y | Y | Y | Y | Y | Y | Y | Y |  |  |
| Amrein/VITdAL-ICU 2014 | High dose Vitamin D3 | 2011 |  | 0% | Y | Y | Y | Y | Y | **Y** | **Y** | Y |  | <0.05 |
| Boom 2014 | Continuous glucose monitoring | 2012 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Bove 2014 | Fenoldopam in AKI (for card surg) | 2010 |  | 0% | Y |  |  |  | Y |  |  |  |  |  |
| Diaz-Prieto 2014 | Early tracheostomy | 2007 |  | 0% |  | Y |  |  | Y |  | Y |  |  |  |
| Harvey/CALORIES 2014 | Early parenteral v enteral feeds | 2012 |  | 0% | **Y** | Y | **Y** | **Y** | Y | Y | Y |  |  | <0.2 |
| Jüttler/DESTINY II 2014 | Hemicraniect. (for MCA CVA) | 2011 |  | 0% |  |  | **Y** | **Y** | **Y** | **Y** | **Y** | **Y** |  | <0.05 |
| Kalfon/CGAO–REA 2014 | Comput. Inten. insulin ther. | 2010 |  | 0% | Y | Y |  |  | Y |  | Y |  |  |  |
| Lellouche 2014 | HME vs HH4 (for NIV) | 2003 |  | 0% | **Y** | Y | Y | Y | Y |  |  |  |  | <0.2 |
| Mazano 2014 | Q2h v Q4h repositioning | 2010 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Meyer/PEITHO 2014 | Fibrinolysis (for intermed. risk PE) | 2010 |  | 0% |  |  | Y |  | Y |  |  |  |  |  |
| Pearse/OPTIMISE 2014 | CO guided therapy peri-op | 2011 |  | 0% |  |  | **Y** | Y | Y | Y | Y | **Y** |  | <0.2 |
| Pérez-Bárcena 2014 | IV glutamine (for trauma) | 2011 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Robertson 2014 | Restrictive transfus. (for TBI) | 2009 |  | 100% |  |  | **Y** | Y | Y | Y | Y | Y |  | <0.2 |
| Robertson 2014\* | Erythropoietin (for TBI) | 2009 |  | 100% |  |  | Y | Y | Y | Y | Y | Y |  |  |
| Schefold/CONVINT 2014 | Contin v intermit dialysis | 2004 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Schindler/CASH 2014 | Citrate v heparin (for CRRT) | 2008 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Seguin 2014 | Oropharyngeal povidone I2 | 2009 |  | 0% | Y |  |  |  |  |  | Y |  |  |  |
| van Zantan/MetaPlus 2014 | Immunonutrition | 2011 |  | 0% | Y | Y | **Y** | **Y** | Y | Y | **Y** | Y |  | <0.2 |
| Zhou 2014 | Combined propofol+midaz. | 2010 |  | 0%-Chi | Y | Y |  |  |  |  |  |  |  |  |
| Andrews/ Eurotherm3235 2015 | Hypothermia(for ICH in TBI) | 2012 | Y | 0% |  |  | Y | **Y** | **Y** | **Y** | **Y** | Y |  | <0.05 |
| Arabi/PermiT 2015 | Permissive underfeeding | 2012 |  | 0%-KSA | Y | Y | Y | Y | Y | Y | Y | Y |  |  |
| Doig 2015 | IV amino acids | 2012 |  | 0% | Y | Y |  |  |  |  | Y |  |  |  |
| Gattas 2015 | Citrate v heparin (for CRRT) | 2011 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Lacroix/ABLE 2015 | Fresh v standard age pRBC | 2011 |  | 0% | **Y** | Y | Y | Y | Y | Y | Y |  |  | <0.2 |
| Mesejo 2015 | Diabetic feeds (for hyperglyc.) | 2011 |  | 0% |  |  |  |  | Y |  |  | Y |  |  |
| Mimoz/CLEAN 2015 | Chlorhexidine v povidone I2 | 2013 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Mimoz/CLEAN 2015 | Scrubbing for CVC insertion | 2013 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Murphy/TiTRE2 2015 | Liberal transfus (for card surg) | 2011 |  | 0% |  |  | Y | Y | Y | Y | **Y** |  |  | <0.05 |
| Nichol/EPO-TBI 2015 | EPO in TBI | 2012 |  | 0% |  |  | **Y** | **Y** | **Y** | **Y** | **Y** | ***Y****(<.2)* |  | <0.05 |
| Souweine 2015 | EtOH lock (for HD CVC) | 2010 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Stucker 2015 | Citrate v heparin (for CRRT) | 2012 |  | 0% |  |  |  |  | Y |  | Y |  |  |  |
| Whitlock/SIRS 2015 | Steroids (for card surgery) | 2010 |  | 9% |  |  | Y | Y | **Y** | Y | **Y** | Y |  | <0.2 |
| Zarbock/RenalRIPC 2015 | Ischem precond (for card surg) | 2014 |  | 0% |  | Y |  |  | Y |  |  |  |  |  |
| Bandeshe 2016^ | Inhaled heparin | 2012 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Barbosa 2016 | Magnesium | 2013 |  | 0%-Bra | Y | **Y** |  |  |  |  |  |  |  | <0.2 |
| Demoule 2016 | NAVA v PSV weaning | 2012 |  | 0% | Y |  |  |  | Y |  |  |  |  |  |
| Gaudry/AKIKI 2016 | Early RRT | 2014 |  | 0% |  |  | Y | Y | Y | Y |  |  |  |  |
| Girardis/Oxygen-ICU 2016 | SpO2 94-98% v 97-100% | 2011 |  | 0% | **Y** | **Y** | **Y** | **Y** | **Y** |  |  |  |  | <0.05 |
| Gobatto/TRACHUS 2016 | U/S v Bronch guided perc trach | 2014 |  | 0%-Bra | Y | Y |  |  |  |  |  |  |  |  |
| Hernandez 2016 | HFNC v O2 (low risk extub) | 2013 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Hernandez 2016 | NIV v HFNC (high risk extub) | 2013 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| IRONMAN 2016 | IV iron | 2014 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Jaber/NIVAS 2016 | NIV (abdominal surgery) | 2014 |  | 0% |  |  | Y | **Y** | **Y** | **Y** | **Y** |  |  | <0.2 |
| Legriel/HYPERNATUS 2016 | Hypotherm (status epilept.) | 2013 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Morris 2016 | Standardized rehabilitation | 2012 |  | 100% |  | Y |  |  |  |  |  | Y |  |  |
| Moss 2016 | Intensive physiotherapy | 2012 |  | 100% | Y | Y |  |  | Y |  | Y | Y |  |  |
| Panwar 2016 | SpO2 88-92% v ≥96% | 2014 |  | 0% | Y |  |  |  |  |  | Y |  |  |  |
| Schaller 2016 | Early mobilisation | 2014 | Y | 60% |  | **Y** |  |  |  |  | Y |  |  | <0.2 |
| Schmid 2016 | Early Goal Directed Therapy | 2011 |  | 0% |  | Y |  |  |  |  |  |  | Y |  |
| Selvanderan/POP-UP 2016 | Pantoprazole | 2015 | Y | 0% |  |  | **Y** | Y | Y | Y | Y |  |  | <0.2 |
| Swan/CHG-BATH 2016 | Chlorhexidine bath | 2012 |  | 100% | Y | Y |  |  |  |  |  |  |  |  |
| Zeng 2016 | Probiotics | 2012 |  | 0%-Chi | Y | Y |  |  |  |  |  |  |  |  |
| Allingstrup/EAT-ICU 2017 | Early parenteral nutrition | 2015 |  | 0% |  |  |  |  | Y | Y | Y | Y |  |  |
| Cooper/TRANSFUSE 2017 | Fresh v oldest pRBC | 2014 |  | 0% |  |  | Y | Y | Y | Y | Y | Y |  |  |
| Dubois/LOGIC-2 2017 | Automated v nurse IIT | 2014 |  | 0% | Y | Y |  |  |  |  | Y |  |  |  |
| Landoni/CHEETAH 2017 | Levosimendan (card. surg) | 2013 | Y | 0% | Y | Y | **Y** | Y | Y | Y | Y | Y |  | <0.2 |
| Lascarrou 2017 | Video v direct laryngoscopy | 2015 |  | 0% | Y |  |  |  | Y |  |  |  |  |  |
| Li Bassi 2017 | Semirecumb. v lat. Trendel. | 2013 |  | <10% | **Y** | Y | Y | Y | Y |  |  |  |  | <0.2 |
| Mehta/LEVO-CTS 2017 | Levosimendan (card. surg) | 2015 |  | 10-90% |  |  | Y | ***Y*** *( <.05)* | Y | **Y** | **Y** |  |  | <0.2 |
| Vargas/VHYPER 2017 | NIV post extubation | 2010 |  | 0% | **Y** |  | Y | **Y** | **Y** | Y | Y |  |  | <0.2 |
| Wischmeyer/TOP-UP 2017 | Suppl. parenteral nutrition | 2013 |  | 10-90% | Y | Y |  |  |  |  |  | Y |  |  |
| Yasuda 2017\* | Chlorhexidine v povidone I2 | 2013 |  | 0%-Jap | **Y** | Y |  |  |  |  |  |  |  | <0.2 |
| Zhang 2017 | Shenfu post cardiac arrest | 2013 |  | 0%-Chi |  |  | **Y** | **Y** | **Y** | **Y** | **Y** |  |  | <0.05 |
| Daubin 2018 | Procalcitonin guided abx in COPD | 2013 | Y | 0% | Y |  |  |  | Y |  | **Y** |  |  | <0.2 |
| Fossat 2018 | In-bed cycling | 2015 | Y | 0% | Y | Y |  |  | **Y** |  |  | Y |  | <0.2 |
| Girard/MIND-USA 2018\* | Anti-psychotics | 2014 |  | 100% |  |  | Y | Y | Y | Y |  |  |  |  |
| Klarin 2018 | Oral lactobacill. v chlorhex. | 2009 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Krag/SUP-ICU 2018 | Pantoprazole | 2016 | Y | 0% |  |  | Y | **Y** | Y | Y | Y |  |  | <0.2 |
| McWilliams 2018 | Enhanced rehabilitation | 2017 |  | 0% | Y | Y |  |  |  |  | Y |  |  |  |
| Perkins/BREATHE 2018 | NIV weaning | 2015 |  | 0% | Y | Y |  |  | Y |  | Y | Y |  |  |
| PReVENT 2018 | Lung protect. vent. (no ALI) | 2016 | Y | 0% | ***Y*** *(<.2)* | Y | **Y** | Y | Y | Y | Y |  |  | <0.05 |
| Reignier/NUTRIREA2 2018 | Parenteral v enteral feeds | 2014 |  | 0% | Y | Y |  |  | Y |  | Y |  |  |  |
| Ridley 2018 | Suppl. parenteral nutrition | 2015 |  | 0% | Y | Y |  |  |  |  | Y | Y |  |  |
| Sarfati 2018 | Rehabil. with passive tilting | 2014 |  | 0% | **Y** | **Y** |  |  |  |  |  |  |  | <0.05 |
| TARGET 2018 | Concentrated enteral feeds | 2017 |  | 0% |  | Y | Y | Y | Y | Y | Y |  |  |  |
| van den Boorgaard/ REDUCE 2018\* | Haldoperidol | 2015 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| van Meenan 2018 | Prn v sched NAC & ventolin | 2015 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Zhu 2018 | Post pyloric feeding | 2016 |  | 0%-Chi | Y | Y |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Sepsis** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Greenman 1991 | E5 murine endotoxin Ab | 1988 |  | 100% |  |  | Y | Y | Y |  |  |  |  |  |
| Dhainaut 1994 | Platelet-act factor antagon. | 1991 |  | 0% |  |  | Y | Y | **Y** |  |  |  |  | <0.2 |
| Fisher 1994\* | IL-1 receptor antagonist | n/r |  | 10-90% |  |  | **Y** | **Y** | Y |  |  |  |  | <0.2 |
| Abraham/NORSEPT I 1995\* | TNFα Ab | 1991 |  | 90% |  |  | **Y** | **Y** | Y |  |  |  |  | <0.2 |
| Bone 1995 | E5 murine endotoxin Ab | 1990 | Y | 100% |  |  | **Y** | Y | Y |  |  |  |  | <0.05 |
| Willatts 1995 | Taurolidine(anti-endotoxin) | n/r |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Cohen/INTERSEPT 1996\* | TNFα Ab | 1992 |  | <10% |  |  | Y | Y | Y |  |  |  |  |  |
| Fisher 1996\* | TNFreceptor:Fc fusion prot | n/r | Y | 100% |  |  | **Y** | Y | **Y** |  |  |  |  | <0.2 |
| Opal 1997 | IL-1 receptor antagonist | n/r |  | 10-90% |  |  | Y | Y | Y |  |  |  |  |  |
| Abraham 1997\* | p55 TNF recept fusion prot | n/r |  | 10-90% |  |  | **Y** | **Y** | Y |  |  |  |  | <0.2 |
| Abraham/NORSEPTII 1998 | TNFα Ab | n/r |  | 99% |  |  | Y | Y | Y |  |  |  |  |  |
| Baudo 1998 | Antithrombin III | 1992 |  | 0% | Y |  | Y | Y | Y |  |  |  |  |  |
| Dhainaut 1998 | Platelet-act factor antagon. | 1993 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Angus 2000 | E5 murine endotoxin Ab | 1995 |  | 100% |  |  |  | Y | Y |  |  |  |  |  |
| Abraham 2001 | TissueFactor Pathway Inhib | 1999 |  | 10-90% |  |  | Y | Y | Y |  |  |  |  |  |
| Bernard/PROWESS 2001 | Activated Protein C | 2000 |  | 10-90% |  | **Y**5 | Y | **Y** | **Y** | **Y**5 | Y5 | Y5 | Y5 | <0.05 |
| Reinhart/RAMSES 2001 | TNFα Ab fragment | 1996 |  | 0% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Rivers 2001 | Early Goal DirectedTherapy | 1998 |  | 100% |  | **Y** |  |  | **Y** | **Y** |  |  |  | <0.05 |
| Schortgen 2001 | 6% HES (200/0.6) v gelatin | 1999 |  | 0% | Y |  | Y | Y |  |  |  |  |  |  |
| Warren/KyberSept 2001 | Antithrombin III | 1999 |  | 10-90% |  |  | Y | Y | Y | Y-56d | Y |  |  |  |
| Annane 2002 | Steroids | 1997 |  | 0% | Y | Y | **Y** | Y | Y |  |  |  | Y | <0.05 |
| Busund 2002 | Plasmapheresis | 1996 |  | 0% |  |  | Y | Y | **Y** |  |  |  |  | <0.05 |
| Abraham 2003\* | Phospholipase A2 inhibitor | 1999 | Y | 100% |  |  | **Y** | Y | Y |  |  |  |  | <0.2 |
| Abraham/OPTIMIST 2003 | Tiss Fact Path Inhib INR≥1.2 | 2001 |  | 10-90% |  |  | Y | Y | Y |  |  |  |  |  |
| Abraham/OPTIMIST 2003 | Tiss Fact Path Inhib INR<1.2 | 2001 |  | 10-90% |  |  | Y | Y | **Y** |  |  |  |  | <0.05 |
| Albertson 2003 | Enterobacteriaceae Ag Ab | n/r |  | 100% |  |  | Y | Y | Y |  |  |  |  |  |
| Chastre 2003 | 8d v 15d antibiotics(for VAP) | 2000 |  | 0% |  | Y | Y | Y | Y | Y |  |  |  |  |
| Richard 2003 | Pulmonary artery catheter | 2000 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Root 2003 | G-CSF | 1997 | Y | 10-90% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Shuster 2003 | Platelet-activating factor | 1999 |  | 100% |  |  | Y | **Y** | **Y** |  |  |  |  | <0.05 |
| Opal/COMPASS 2004 | Platelet-activating factor | 2002 |  | 10-90% |  |  | Y | Y | Y |  |  |  |  |  |
| Bakker 2004 | NO synthase inhibitor | n/r |  | 26% |  |  | Y | Y | Y |  |  |  |  |  |
| López 2004 | NO synthase inhibitor | 1997 | Y | 10-90% |  |  | **Y** | **Y** | **Y** | **Y** | **Y** |  |  | <0.05 |
| Panacek/MONARCS 2004 | TNFα Ab F(ab’)2 fragment | 1997 |  | >80% |  |  | **Y** | Y | **Y** |  |  |  |  | <0.05 |
| Reinhart 2004 | Extracorp endotox absorb | n/r |  | 0% |  |  | Y |  | Y |  |  |  |  |  |
| Abraham/ADDRESS 2005 | Activated Protein C | 2003 |  | ~40% |  | Y | Y | Y | Y | Y6 | Y6 | Y6 | Y6 |  |
| Lin 2006 | Early Goal DirectedTherapy | 2003 |  | 0%-Tai | **Y** | **Y** |  |  |  |  |  |  |  | <0.05 |
| Hentrich 2006 | IgMA-enrich IVIg (for neutropen.) | 1996 |  | 0% |  |  |  |  | Y | Y |  |  |  |  |
| Pontes-Arruda 2006 | Immunonutrition | n/r |  | 0%-Bra |  |  | Y | **Y** | **Y** |  |  |  |  | <0.05 |
| Angstwurm 2007 | Selenium | 2002 |  | 0% |  |  | Y | **Y** | Y |  |  |  |  | <0.05 |
| Annane/CATS 2007 | Norepi+Dobut v Epi | 2002 |  | 0% | Y | Y | Y | **Y** | Y | Y | Y |  |  | <0.2 |
| Levi/XPRESS 2007 | Heparin (in act prot C) | 2004 |  | ~45% |  |  | Y | **Y** | **Y** |  |  |  |  | <0.2 |
| Werdan/SBITS 2007 | IVIg v albumin | 1993 |  | 0% | Y |  | Y | Y | Y | Y | **Y** |  |  | <0.05 |
| Brunkhorst 2008 | Intensive insulin therapy | 2004 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Brunkhorst 2008 | 10% HES (200/0.5) v Ringers | 2004 | Y | 0% |  |  | Y | Y | Y | **Y** | **Y** |  |  | <0.2 |
| Russell/VASST 2008 | Vasopressin v NorEpi | 2003 |  | <10% |  |  | Y | Y | Y | **Y** | **Y** |  |  | <0.2 |
| Sprung/CORTICUS 2008 | Steroids | 2004 |  | 0% | Y | Y | **Y** | Y | Y |  |  |  | Y | <0.2 |
| Werdan/ESSICS 2008 | IVIg (for card surg w/ SIRS) | 1998 |  | 0% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Dellinger/LIPOS 2009\* | Phospholipid emulsion | 2005 |  | 13% |  |  | Y | Y | Y |  |  |  |  |  |
| Dhainaut 2009 | Activated Protein C 7 v 4d | 2006 | Y | 10-90% |  | **Y** |  |  | Y |  |  |  |  | <0.2 |
| Dupont 2009 | Lipo Ampho B v micafungin | 2003 |  | <10% |  |  | Y-8d | Y | Y | Y | Y |  |  |  |
| Jaimes/HETRASE 2009 | Heparin | 2006 |  | 0%-Col |  | Y | Y | Y | Y |  |  |  |  |  |
| Palizas 2009 | Gastric tonometry | 1999 |  | 0%SAm |  |  | Y | Y | Y |  |  |  |  |  |
| Bouadma/PRORATA 2010 | Procalcitonin guided abx | 2007 |  | 0% |  |  | Y | Y | Y | Y |  |  |  |  |
| De Backer/SOAP II 2010 | NorEpi v dopamine (all shock) | 2005 |  | 0% | Y | Y | **Y** | Y | Y |  |  | Y | Y | <0.05 |
| Jansen/LACTATE 2010 | Lactate-guided resuscitation | 2007 |  | 0% | Y | Y | Y | Y | Y | Y | **Y** | Y |  | <0.05 |
| Patel 2010 | NorEpi v dopamine | 2006 |  | 100% |  |  | **Y** | Y | Y |  |  |  |  | <0.2 |
| Rice 2010\* | Toll-like receptor 4 inhibitor | 2008 |  | 10-90% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Tidswell 2010\* | Toll-like receptor 4 inhibitor | 2003 |  | 90% |  |  | Y | Y | Y |  |  |  |  |  |
| Jensen/PASS 2011 | Procalcitonin guided abx | 2007 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Pontes-Arruda/ INTERCEPT 2011 | Immunonutrition (Oxepa) | 2008 |  | 0%-Bra |  |  | Y | **Y** | Y |  |  |  |  | <0.05 |
| Brunkhorst 2012 | Dual v single antibiotics | 2009 |  | 0% |  |  | Y | Y | Y | Y-56d | Y |  |  |  |
| Chytra 2012 | Continuous v intermittent abx | 2009 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Guidet/CHRYSTMAS 2012 | 6% HES (130/0.4) v 0.9% NS | 2009 |  | 0% |  |  |  |  | Y |  | Y |  |  |  |
| Kim 2012 | Broad spectrum abx(for HAP) | 2005 | Y | 0%-Kor |  | Y |  | Y | **Y** |  |  |  |  | <0.2 |
| Perner/6S 2012 | 6% HES (130/0.42) v Ringers | 2010 | Y | 0% |  |  | Y | Y | Y | **Y** | **Y** | Y7 | Y7 | <0.05 |
| Ranieri/PROWESS SHOCK 2012 | Activated Protein C | 2009 | Y | 10-90% |  |  | Y | **Y** | Y | Y | Y |  |  | <0.2 |
| Schortgen/Sepsiscool2012 | External cooling (for fever) | 2008 |  | 0% | Y | Y | **Y** | **Y** |  |  |  |  |  | <0.05 |
| Trof 2012 | Pressure v Volume Hemodyn.8 | 2008 |  | 0% | Y | Y | **Y** | Y | Y |  |  |  |  | <0.2 |
| Annane/APROCCHSS 2013 | Activated Protein C | 2010 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Guntupalli 2013 | Talactoferrin | 2008 |  | 100% |  |  | Y | Y | **Y** | Y | Y | **Y** |  | <0.05 |
| Joannes-Boyau/IVOIRE 2013 | High-volume hemofiltration | 2008 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Kruger/ANZ-STATInS 2013 | Atorvastatin | 2009 |  | 0% | Y | Y |  |  | **Y** |  | Y |  |  | <0.2 |
| Morelli 2013 | Esmolol | 2011 |  | 0% | **Y** | **Y** | **Y** | **Y** | **Y** |  |  |  |  | <0.05 |
| Opal/ACCESS 2013 | Toll-like receptor 4 inhibitor | 2008 |  |  |  |  | Y | Y | Y | Y | Y | Y | Y |  |
| Vincent 2013 | Thrombomodulin (for DIC) | 2008 |  | 16% |  |  | Y | Y | **Y** |  |  |  |  | <0.2 |
| Wu/ETASS 2013 | Thymosin alpha 1 | 2009 |  | 0%-Chi | Y | **Y** | Y | Y | Y |  |  |  |  | <0.05 |
| ARISE 2014 | Early Goal DirectedTherapy | 2011 |  | 0% | Y | Y | Y | **Y** | Y | Y | Y |  |  | <0.2 |
| Asfar/SEPISPAM 2014 | Mean BP 80 v 65 mm Hg | 2011 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Bernard 2014 | TNFα Ab fragment | 2011 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Caironi/ALBIOS 2014 | Albumin (for level <30 g/L) | 2010 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Holst/TRISS 2014 | Restrictive transfusion | 2012 |  | 0% |  |  | Y-5d | Y | Y | Y | Y | Y16 | Y16 |  |
| Karnard 2014 | Ulinastatin (trypsin inhibitor) | 2010 |  | 0%-Ind |  |  | Y | Y | **Y** |  |  |  |  | <0.2 |
| Leone/AZUREA 2014 | Deescal v contin empir abx | 2012 |  | 0% |  | Y | Y | Y | Y | Y | Y |  |  |  |
| ProCESS 2014^ | Early Goal DirectedTherapy | 2010 |  | 100% |  |  | Y | Y | Y | Y | Y | Y | Y |  |
| Shehabi/ProGUARD 2014 | Procalcitonin guided abx | 2012 |  | 0% | Y | Y |  |  |  |  | Y |  |  |  |
| Dulhunty/BLING II 2015 | Continuous v intermittent abx | 2013 |  | 0% | Y | Y | Y | Y | Y | Y | Y |  |  |  |
| Mouncey/ProMISe2015 | Early Goal DirectedTherapy | 2012 |  | 0% |  | Y | Y | Y | Y | Y | Y |  |  |  |
| Payen/ABDOMIX 2015 | Polymyxin B hemoperfusion | 2012 | Y | 0% |  |  | Y | Y | **Y** | **Y** | **Y** |  |  | <0.2 |
| Vincent/OASIS 2015 | Talactoferrin | 2012 | Y | 10-90% |  | **Y** | Y | Y | Y |  | **Y** |  |  | <0.05 |
| Young/HEAT 2015 | Acetominophen (for fever) | 2013 |  | 0% |  |  | **Y** | Y | Y | Y | Y |  |  | <0.05 |
| Zhang 2015 | Volume v Pressure Hemodyn.9 | 2013 |  | 0%-Chi |  |  |  | Y | Y |  |  |  |  |  |
| Abdul-Aziz/BLISS 2016 | Continuous v intermittent abx | 2013 |  | 0%-Mal | Y |  | **Y** | Y | **Y** |  |  |  |  | <0.2 |
| Gordon/VANISH 2016 | Vasopressin v norepineph. | 2014 |  | 0% | Y | Y | Y | **Y** | Y |  |  |  |  | <0.2 |
| Gordon/VANISH 2016 | Steroids | 2014 |  | 0% | Y | Y | Y | Y | Y |  |  |  |  |  |
| Hjortrup/CLASSIC 2016 | Fluid restriction | 2015 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Hyvernet 2016 | Contin. v intermit. Steroids | 2009 |  | 0% | Y | Y | **Y** | ***Y*** *(<.2)* | Y |  | Y |  |  | <0.05 |
| Keh/HYPRESS 2016 | Steroids | 2011 |  | 0% | Y | Y | Y | Y | Y | Y | Y | Y |  |  |
| Timsit/EMPIRICUS 2016 | Micafungin | 2013 | Y | 0% |  |  | **Y** | Y | Y | Y | Y |  |  | <0.2 |
| Tongyoo 2016 | Steroids | 2012 |  | 0%-Thai |  |  | Y | Y | Y | Y |  |  |  |  |
| Bergamin/TRICOP 2017 | Liberal v restrictive transfxn | 2013 |  | 0%-Bra | ***Y*** *(<.2)* |  | Y | ***Y*** *(<.2)* | ***Y****(<.2)* | ***Y****(<.2)* | **Y** |  |  | <0.05 |
| Kawazoe/DESIRE 2017 | Dexmedetomidine | 2014 |  | 0%-Jap |  |  | Y | **Y** | **Y** |  |  |  |  | <0.2 |
| Limaye 2017 | Gancyclovir | 2013 |  | 100% |  |  | Y | Y | Y | Y | Y | Y |  |  |
| Madsen/INSTINCT 2017 | IVIg | 2015 |  | 0% |  |  | Y | Y | Y | Y | Y | Y |  |  |
| Rouzé/S-TAFE 2017 | Biomarker guided anti-fungal | 2015 |  | 0% | Y |  |  |  | Y |  |  |  |  |  |
| Zhou 2017 | Lactate v ScvO2 resuscitation | 2014 |  | 0%-Chi |  |  | Y | ***Y*** *(<.2)* | **Y** | **Y** |  |  |  | <0.05 |
| Annane/APROCCHSS 2018 | Steroids | 2012 |  | 0% | **Y** | **Y** | **Y** | ***Y*** *(<.2)* | ***Y****(<.2)* | **Y** | **Y** | **Y** |  | <0.05 |
| Barbar/IDEAL-ICU 2018 | Early RRT | 2014 |  | 0% | Y | Y | Y | Y | Y | Y | Y | Y |  |  |
| Dellinger/EUPHRATES 2018 | Polymyxin B hemoperfusion | 2013 | Y | 10-90% |  |  | Y | Y | Y |  | Y | **Y** |  | <0.2 |
| Montravers/ DURAPOP 2018 | 8d v 15d abx (for abdo infxn) | 2013 |  | 0% |  |  | Y | **Y** | Y |  |  |  |  | <0.2 |
| Venkatesh/ADRENAL 2018 | Steroids | 2015 |  | 0% |  |  | ***Y****(<.2)* | **Y** | ***Y****(<.2)* | Y | Y |  |  | <0.05 |
| Welte/CIGMA 2018 | IVIg (ventilated CAP) | 2012 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **ARDS** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anzueto 1996 | Surfactant | 1992 | Y | 10-90% |  |  | **Y** | Y | Y |  |  |  |  | <0.2 |
| Brochard 1998 | Lung Protective Ventilation | 1995 |  | 10-90% |  |  | Y | Y | Y | Y |  |  |  |  |
| Stewart 1998 | Lung Protective Ventilation | 1996 |  | 0% | Y | Y | Y | Y | Y |  |  |  |  |  |
| Lundin 1999 | Inhaled NO | 1995 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| ARDS Net 200010 | Ketoconazole | 1996 |  | 100% |  | Y | Y | Y | Y | Y | Y | Y |  |  |
| ARDS Net 200010 | Lung Protective Ventilation | 1997 |  | 100% |  | **Y** | Y | **Y** | **Y** | **Y** | **Y** | **Y** |  | <0.05 |
| Delclaux 2000 | CPAP v oxygen | 1998 |  | 0% | Y | Y |  |  |  |  |  |  |  |  |
| Gattinoni/PS I 2001 | Prone ventilation | 1998 |  | 0% | Y |  | **Y**-10d | Y | Y | Y | Y | Y |  | <0.2 |
| ARDS Net 200210 | Lisofylline | 1998 | Y | 100% |  |  | Y | Y | **Y** |  |  |  |  | <0.2 |
| Derdak/MOAT 2002 | High frequency oscillation | 1999 |  | ~70% |  |  | Y | **Y** | **Y** | **Y** | **Y** | **Y** |  | <0.2 |
| Fernández-Vivas 2003 | (Non-invasive) PAV v PSV | 2001 |  | 0% | Y | Y | Y | Y | Y |  |  |  |  |  |
| Ferrer 2003 | BiPAP v oxygen | n/r |  | 0% | **Y** |  | Y | Y | **Y** | **Y** | **Y** |  |  | <0.05 |
| ARDS Net/ALVEOLI 2004 | High v low PEEP | 2000 |  | 100% |  |  | Y | Y | Y | Y |  |  |  |  |
| Guerin 2004 | Prone ventilation | 2000 |  | 0% |  |  | Y | Y | Y | Y | Y |  |  |  |
| Zeiher/STRIVE 2004 | Neutrophil elastase inhib | 2002 | Y | 10-90% |  |  | Y | Y | Y | Y | Y | **Y** |  | <0.05 |
| ARDS Net/FACCT 2006 | Conservative fluid mgmt.11 | 2003 |  | >90% |  |  | Y | Y | **Y** | Y |  |  |  | <0.2 |
| ARDS Net/FACCT 2006 | Pulmonary artery catheter11 | 2003 |  | >90% |  |  | Y | Y | Y | Y |  |  |  |  |
| ARDS Net/LaSRS 2006 | Late steroids12 | 2000 |  | 100% |  |  | Y | Y | Y | Y | Y | Y |  |  |
| Kacmarek 2006\* | Partial liquid ventilation | 1999 | Y | 10-90% |  |  | Y | **Y** | **Y** |  |  |  |  | <0.2 |
| Mancebo 2006 | Prone ventilation | 2000 |  | 0% | **Y** | **Y** | Y | Y | **Y** | **Y** |  |  |  | <0.2 |
| Villar/ARIES 2006 | Low Vt and high PEEP | 2000 |  | 0% | **Y** | **Y** |  | Y |  |  |  |  |  | <0.05 |
| Meade/LOVS 2008 | High v low PEEP | 2003 |  | 0% | **Y** | Y | Y | Y | **Y** |  |  |  |  | <0.2 |
| Mercat/EXPRESS 2008 | High v low PEEP | 2004 |  | 0% |  | Y | **Y** | Y | Y | Y |  |  |  | <0.05 |
| Morris 2008 | Oxothiazolidine | 1997 | Y | >90% |  |  | Y | Y | **Y** |  |  |  |  | <0.05 |
| Kesecioglu 2009 | Surfactant | 2003 | Y | 0% |  |  | Y | Y | **Y** | **Y** | **Y** | **Y** |  | <0.2 |
| Peek/CESAR 2009 | ECMO | 2004 |  | 0% |  |  | Y | **Y** | **Y** | **Y** | **Y** | Y |  | <0.05 |
| Taccone/PS II 2009 | Prone ventilation | 2006 |  | 0% | Y |  | Y | Y | Y | **Y** | Y | Y |  | <0.2 |
| Vincent 2009\* | Act Fac VII | n/r |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Azoulay 2010 | BAL v sput cx (non-intub heme-onc) | 2006 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Determann 2010 | Lung Protective Ventilation | 2006 |  | 0% |  |  | Y | Y | Y |  |  |  |  |  |
| Papazian/ACURASYS 2010 | Paralysis | 2007 |  | 0% | Y | Y | Y | Y | **Y** | Y | Y |  |  | <0.05 |
| Spragg 2011 | Surfactant | 2006 |  | 17% |  |  | Y | **Y** | Y |  | Y | Y |  | <0.2 |
| ARDS Net/ALTA 2011 | Inhaled β2-agonist (albuterol)13 | 2008 | Y | 100% |  |  | **Y** | **Y** | **Y** | Y | Y |  |  | <0.2 |
| Rice/OMEGA 2011 | Omega-3 enteral feeding14 | 2008 | Y | 100% |  |  | Y | Y | Y | **Y** |  |  |  | <0.05 |
| ARDS Net/EDEN 2012 | Permissive underfeeding14 | 2010 |  | 100% |  | Y | Y | Y | Y | Y | Y | Y | Y |  |
| Gao Smith/BALTI-2 2012 | IV β2-agonist (salbutamol) | 2008 | Y | 0% | Y | Y | Y | Y | **Y** |  |  |  |  | <0.05 |
| Paine 2012 | GM-CSF | 2006 |  | 100% |  |  | **Y** | **Y** | Y |  |  | Y |  | <0.2 |
| Ferguson/OSCILLATE 2013 | High frequency oscillation | 2010 | Y | 10-90% | **Y** | **Y** | **Y** | **Y** | **Y** |  |  |  |  | <0.05 |
| Guérin/PROSEVA 2013 | Prone ventilation | 2009 |  | 0% |  |  | **Y** | **Y** | **Y** | **Y** | **Y** |  |  | <0.05 |
| Young/OSCAR 2013 | High frequency oscillation | 2010 |  | 0% | Y | Y | Y | Y | Y |  |  |  |  |  |
| ARDS Net/SAILS 2014 | Rosuvastatin15 | 2011 |  | 100% |  |  | Y | Y | Y | Y | Y |  |  |  |
| McAuley/HARP-2 2014 | Simvistatin | 2012 |  | 0% | Y | **Y** | Y | Y | **Y** | **Y**17 | **Y**17 | **Y**17 | **Y**17 | <0.2 |
| Lemiale/GRRR-OH 2015 | BiPAP v oxygen (immunocomp) | 2014 |  | 0% | Y | Y | Y | Y | Y |  |  | Y |  |  |
| Willson/CARDS 2015 | Surfactant | 2009 |  | 10-90% |  | Y |  |  |  |  | Y |  |  |  |
| Kacmarek 2016 | Decremental PEEP & recruit | 2011 |  | <10% | Y | Y |  |  | Y | Y |  |  |  |  |
| ART 2017 | Recruit. & titrated PEEP | 2014 | Y | 0% | ***Y*** *(<.2)* | ***Y****(<.2)* | **Y** | **Y** | ***Y****(<.2)* |  |  |  |  |  |
| Azoulay/HIGH 2018 | HFNC v face mask oxygen | 2017 |  | 0% | Y | Y | Y | Y | Y |  |  |  |  |  |
| Coombes/EOLIA 2018 | ECMO | 2014 |  | <10% | ***Y*** *(<.2)* | ***Y****(<.2)* | ***Y****(<.2)* | **Y** | ***Y****(<.2)* | ***Y****(<.2)* | ***Y*** *(<.2)* |  |  | <0.05 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Description of Column Headings and Abbreviations within the Table

“Enrol Year”-median year of trial enrolment.

“Y”-mortality reported at prespecified time point by the trial.

“Harm”- trials Yhere intervention group mortality was higher than control group mortality with p<0.2 at any of the prespecified time points (indicated by “R” in this column).

“Min p”-identifies trials where p<0.05 or p<0.2 at time points indicated with a bold underlined “**Y**”.

Trials not conducted in North America, Europe, or Australia/New Zealand have countries identified (Arg-Argentina, Bra-Brazil, Chi-China, Col-Columbia, HK-Hong Kong, Ind-India, Isr-Israel, Jap-Japan, Kor-Korea, KSA-Kingdom of Saudi Arabia, Mal-Malaysia, SAfr-South Africa, SAm-South America, Tai-Taiwan, Thai-Thailand, Viet-Vietnam)

Footnotes

\*Combined two intervention groups, or two or more dose groups.

^Combined two control groups.

0Published trial designed as 30 v 120 min T-piece spontaneous breathing trial (SBT).

1Followed to 28d; patients discharged alive from hospital before 90 days assumed in publication to still be alive at 90 days.

2Followed to hospital discharge with mean hospital length of stay >50 days. 7d, 14d, and 28d mortality estimated from published survival curve.

3Mortality at median follow up of 873d (2.4y, IQR 1.5-3.3y).

4Published trial designed as heated humidifier (HH) v heat and moisture exchanger (HME).

5Mortality beyond 28 days reported separately in Angus et al, Crit Care Med 2004; 32(11): 2199-206.

6Mortality beyond 28 days reported separately in Laterre et al, Crit Care Med 2007; 35(6): 1457-63.

7Mortality beyond 90 days reported separately in Perner et al, Inten Care Med 2014; 40: 1457-63.

8Published trial designed as volume-guided management using transpulmonary thermodilution (PiCCO system) v pressure-guided management using a pulmonary artery catheter.

9Volume-guided management using transpulmonary thermodilution (PiCCO system) v pressure-guided management using central venous pressure.

102×2 factorial (initially lung protective ventilation with ketoconazole, then with lisofylline after ketoconazole arm stopped early for futility, and finally lisofylline alone after lung protective ventilation arm stopped early for efficacy). For lung protection ventilation and ketoconazole interventions, patients were followed until day 180 or until they were discharged home without the use of assisted ventilation. (Patients who went home before day 180 without the use of assisted ventilation were assumed to be alive at 180 days.) For lisofylline, all patients were followed for 30 days after hospital discharge as per FDA request with only one additional death occurring after hospital discharge (Schoenfeld D. Crit Care 2006; 10: 103).

112×2 factorial. Patients were followed until day 60 (the primary outcome) or until they were discharged home without the use of assisted ventilation. (Patients who went home before day 60 without the use of assisted ventilation were assumed to be alive at 60 days.)

12All patients had complete 180-day follow-up for survival status.

13ALTA had partial co-enrolment with OMEGA/EDEN and followed patients until day 90 or until discharge home (from hospital, rehabilitation, or chronic ventilator facilities) without the use of assisted ventilation.

142×2 factorial until OMEGA arm stopped early for futility. For OMEGA, patients were followed until day 60 or until discharge home (from hospital, rehabilitation, or chronic ventilator facilities) without the use of assisted ventilation. For EDEN, patients were followed to 12 months in a separate report (Needham et al, BMJ 2013; 346: f1532).

1581 patients were co-enrolled with EDEN. SAILS followed patients until day 60 or until discharge home (from hospital, rehabilitation, or chronic ventilator facilities) without the use of assisted ventilation.

16Mortality beyond 90 days reported separately in Rygård et al, Inten Care Med 2016; 42: 1685-94.

17Mortality beyond 28 days reported separately in Agus et al, Crit Care 2017; 21: 108.

RCT References:

**Non-Sepsis/SIRS, Non-ALI/ARDS**

Gutierrez G, Palizas F, Doglio G, Wainsztein N, Gallesio A, Pacin J, Dubin A, Schiavi E, Jorge M, Pusajo J, Klein F, San Roman E, Dorfman B, Shottlender J, Giniger R. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339: 195-9.

Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.

Hammond JMJ, Potgieter PD, Saunders GL, Forder AA. Double-blind study of selective decontamination of the digestive tract in intensive care. Lancet 1992; 340: 5-9.

Korinek AM, Laisne MJ, Nicolas MH, Raskine L, Deroin V, Sanson-Lepors MJ. Selective decontamination of the digestive tract in neurosurgical intensive care unit patients: a double-blind, randomized, placebo-controlled study. Crit Care Med 1993; 21(10): 1466-73.

Ben-Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, Divine G, Verter J, Bresalier RS. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994; 121: 568-75.

Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330(24): 1717-22.

Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R; for the SvO2 Collaborative Group. A trial of goal-oriented hemodyamic therapy in critically ill patients. N Engl J Med 1995; 333(16): 1025-32.

Atkinson S, Sieffert E, Bihari D. A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Crit Care Med 1998; 26(7): 1164-72.

Corwin HL, Gettinger A, Rodriguez R, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27(11): 2346-50.

Esteban E, Alía I, Tobin MJ, Gil A, Gordo F, Vallverdú I, Blanch L, Bonet A, Vázquez A, de Pablo R, Torres A, de la Cal MA, Macías S; for the Spanish Lung Failure Collaborative Group. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Am J Respir Crit Care Med 1999; 159: 512-8.

Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E; Transfusion Requirements in Critical Care Investigators; for the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340(6): 409-17.

Holzapfel L, Chastang C, Demingeon G, Bohe J, Piralla B, Coupry A. A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1999; 159: 695–701.

Takela J, Ruokonen E, Webster NR, Nielsen MB, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341(11): 785-92.

Bauer P, Charpentier C, Bouchet C, Nace L, Raffy F, Gaconnet C. Parenteral with enteral nutrition in the critically ill. Inten Care Med 2000; 26: 893-900.

Fagon J-Y, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stéphan F, Similowski T, Mercat A, Diehl J-L, Sollet, J-P, Tenaillon A; for the VAP Trial Group. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-30.

Gomersall CD, Joynt GM, Freebairn RC, Hung V, RGN; Buckley TA, Oh TE. Resuscitation of critically ill patients based on the results of gastric tonometry: a prospective, randomized, controlled trial. Crit Care Med 2000; 28(3): 607-14.

Herr DL, Kelly K, Hall JB, Ulatowski J, Fulda GJ, Cason B, Hickey R, Nejman AM, Zaloga GP, Teres D. Safety and efficacy of propofol with EDTA when used for sedation of surgical intensive care unit patients. Inten Care Med 2000; 26: S452-62.

Higgins TL, Murray M, Kett DH, Fulda G, Kramer KM, Gelmont D, Dedhia HV, Levy H, Teres D, Zaloga GP, Ko H, Thompson KA. Trace element homeostasis during continuous sedation with propofol containing EDTA versus other sedatives in critically ill patients. Inten Care Med 2000; 26; S413-21.

Bergmans DCJJ, Bonten MJM, Gaillard CA, Paling JC, van der GEEST S, van TIEL FH, Beysens AJ, de Leeuw PW, Stobberingh EE. Prevention of ventilator-associated pneumonia by oral decontamination. A prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001; 164: 382-8.

Stiell IG, Hebert PC, Wells GA, Vandemheen KL, Tang ASL, Higginson LAJ, Dreyer JF, Clement C, Battram E, Watpool I, Mason S, Klassen T, Weitzman BN. Vasopressin versus epinephrine for in hospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358: 105-9.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345(19): 1359-67.

Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T; for the EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288(22): 2827-35.

Krueger WA, Lenhart F-P, Neeser G, Ruckdeschel G, Schreckhase H, Eissner H-J, Forst H, Eckart J, Peter K, Unertl KE. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients. A prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002; 166: 1029–37.

Ralph CJ, Tanser SJ, Macnaughton PD, Sinclair DG. A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. Inten Care Med 2002; 28: 884-90.

de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003; 362: 1011-6.

Hall JC, Dobb G, Hall J, de Sousa R, Brennan L, McCauley R. A prospective randomized trial of enteral glutamine in critical illness. Inten Care Med 2003; 29: 1710-6.

Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, Kirby A, Jacka M; for the Canadian Critical Care Clinical Trials Group. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348(1): 5-14.

Krishnan JA, Moore D, Robeson C, Rand CS, Fessler HE. A prospective, controlled trial of a protocol-based strategy to discontinue mechanical ventilation. Am J Respir Crit Care Med 2004; 169: 673-8.

Rumbak MJ, Newton M, Truncale T, Schwartz SW, Adams JW, Hazard PB. A prospective, randomized, study comparing early percutaneous dilational tracheotomy to prolonged translaryngeal intubation (delayed tracheotomy) in critically ill medical patients. Crit Care Med 2004; 32(8): 1689–94.

SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350(22): 2247-56.

Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K; on behalf of the PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366: 472-7.

Kieft H, Roos AN, van Drunen JDE, Bindels AJGH, Bindels JG, Hofman Z. Clinical outcome of immunonutrition in a heterogeneous intensive care population. Inten Care Med 2005; 31: 524-32.

Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Crit Care 2005; 9: R687-93.

Boots RJ, George N, Faoagali JL, Druery J, Dean K, Heller RF. Double-heater-wire circuits and heat-and-moisture exchangers and the risk of ventilator-associated pneumonia. Crit Care Med 2006; 34(3): 687–93.

Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355(25): 2619-30.

Ferrer M, Valencia M, Nicolas JM, Bernadich O, Badia JR, Torres A. Early noninvasive ventilation averts extubation failure in patients at risk. A randomized trial. Am J Respir Crit Care Med 2006; 173: 164–70.

Kollef M, Pittet D, García MS, Chastre J, Fagon J-Y, Bonten M, Hyzy R, Fleming TR, Fuchs H, Bellm L, Mercat A, Mañez R, Martínez A, Eggimann P, Daguerre M, Luyt C-E; for the Prevention of Pneumonia Study (POPS-1) Trial Group. Randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006; 173: 91–7.

Lellouche F, Mancebo J, Jolliet P, Roeseler J, Schortgen F, Dojat M, Cabello B, Bouadma L, Rodriguez P, Maggiore S, Reynaert M, Mersmann S, Brochard L. A multicenter randomized trial of computer-driven protocolized weaning from mechanical ventilation. Am J Respir Crit Care Med 2006; 174: 894–900.

Silvester W, Goldsmith D, Uchino S, Bellomo R, Knight S, Seevanayagam S, Brazzale D, McMahon M, Buckmaster J, Hart GK, Opdam H, Pierce RJ, Gutteridge GA. Percutaneous versus surgical tracheostomy: a randomized controlled study with long-term follow-up. Crit Care Med 2006; 34(8): 2145–52.

Thwaites CL, Yen LM, Loan HT, Thuy TTD, Thwaites GE, Stepniewska K, Soni N, White NJ, Farrar JJ. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 2006; 368: 1436–43.

Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354(5): 449-61.

Vinsonneau C, Camus C, Combes A, de Beauregard MAC, Klouche K, Boulain T, Pallot J-L, Chiche J-D, Taupin P, Landais P, Dhainaut J-F; for the Hemodiafe Study Group. Continuous venovenous haemodiafi ltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 2006; 368: 379–85.

van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, Joore HCA, Strack van Schijndel RJM, van der Tweel I, Ramsay G, Bonten MJM. Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. Crit Care Med 2006; 34(2): 396–402.

Chytra I, Pradl R, Bosman R, Pelnář P, Kasal E, Židková A. Esophageal doppler-guided fluid management decreases blood lactate levels in multiple-trauma patients: a randomized controlled trial. Crit Care 2007; 11: R24.

Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ; for the EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357(10): 965-76.

Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA, Dittus RS, Bernard GR, Ely EW. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. The MENDS randomized controlled trial. JAMA 2007; 298(22): 2644-53.

Templeton M, Pallazo MGA. Chest physiotherapy prolongs duration of ventilation in the critically ill ventilated for more than 48 hours. Inten Care Med 2007; 33: 1938-45.

Valencia M, Ferrer M, Farre R, Navajas D, Badia JR, Nicolas JM, Torres A. Automatic control of tracheal tube cuff pressure in ventilated patients in semirecumbent position: a randomized trial. Crit Care Med 2007; 35(6): 1543–9.

Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, Syed SJ, Giridhar HR, Rishu AH, Al-Daker MO, Kahoul SH, Britts RJ, Sakkijha MH. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 2008; 36(12): 3190–97.

Berger MM, Soguel L, Shenkin A, Revelly J-P, Pinget C, Baines M, Chioléro RL. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. Crit Care 2008; 12: R101.

Blot F, Similowski T, Trouillet J-L, Chardon P, Korach J-M, Costa M-A, Journois D, Thiéry G, Fartoukh M, Pipien I, Bruder N, Orlikowski D, Tankere F, Durand-Zaleski I, Auboyer C, Nitenberg G, Holzapfel L, Tenaillon A, Chastre J, Laplanche A. Early tracheotomy versus prolonged endotracheal intubation in unselected severely ill ICU patients. Inten Care Med 2008; 34: 1779–87.

Bucknall TK, Manias E, Presneill JJ. A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. Crit Care Med 2008; 36(5): 1444–50.

Clec’h C, Simon P, Hamdi A, Hamza L, Karoubi P, Fosse J-P, Gonzalez F, Vincent F, Cohen Y. Are daily routine chest radiographs useful in critically ill, mechanically ventilated patients? A randomized study. Inten Care Med 2008; 34: 264–70.

De La Rosa GDC, Donado JH, Restrepo AH, Quintero AM, González LG, Saldarriaga NE, Bedoya M, Toro JM, Velásquez JB, Valencia JC, Arango CM, Aleman PH, Vasquez EM, Chavarriaga JC, Yepes A, Pulido W, Cadavid CA; Grupo de Investigacion en Cuidado intensivo: GICIHPTU. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care 2008; 12: R120.

Desachy A, Clavel M, Vuagnat A, Normand S, Gissot V, François B. Initial efficacy and tolerability of early enteral nutrition with immediate or gradual introduction in intubated patients. Inten Care Med 2008; 34: 1054–9.

Girard TD, Kress JP, Fuchs BD, Thomason JWW, Schweickert WD, Pun BT, Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC, Canonico AE, Light RW, Shintani AK, Thompson JL, Gordon SM, Hall JB, Dittus RS, Bernard GR, Ely EW. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371: 126–34.

Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J; for the 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008; 359(2): 142-51.

Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. Inten Care Med 2008; 34: 2226–34.

VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359(1): 7-20.

Xiao G, Wei J, Yan W, Wang W, Zhenhui L. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12: R61.

Xirouchaki N, Kondili E, Vaporidi K, Xirouchakis G, Klimathianaki M, Gavriilidis G, Alexandopoulou E, Plataki M, Alexopoulou C, Georgopoulos D. Proportional assist ventilation with load-adjustable gain factors in critically ill patients: comparison with pressure support. Inten Care Med 2008; 34: 2026–34.

Ferrer M, Sellarés J, Valencia M, Carrillo A, Gonzalez G, Badia JR, Nicolas JM, Torres A. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet 2009; 374: 1082-8.

Jabre P, Combes X, Lapostolle F, Dhaouadi M, Ricard-Hibon A, Vivien B, Bertrand L, Beltramini A, Gamand P, Albizzati S, Perdrizet D, Lebail G, Chollet-Xemard C, Maxime V, Brun-Buisson C, Lefrant J-Y, Bollaert P-E, Megarbane B, Ricard J-D, Anguel N, Vicaut E, Adnet F; for the KETASED Collaborative Study Group. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374: 293-300.

Knight DJW, Gardiner D, Banks A, Snape SE, Weston VC, Bengmark S, Girling KJ. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial. Inten Care Med 2009; 35: 854-61.

NICE-SUGAR Study Investigators . Intensive versus conventional glucose control in Critically Ill Patients. N Engl J Med 2009; 360(13): 1283-97.

Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PHJ, Wester JPJ, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37(2): 545-52.

Patman S, Jenkins S, Stiller K. Physiotherapy does not prevent, or hasten recovery from, ventilator-associated pneumonia in patients with acquired brain injury. Inten Care Med 2009; 35: 258-65.

Preiser J-C, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chioléro R. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Inten Care Med 2009; 35: 1738-48.

RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361(17): 1627-38.

Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; for the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301(5): 489-99.

Timsit J-F, Schwebel C, Bouadma L, Geffroy A, Garrouste-Orgeas M, Pease S, Herault M-C, Haouache H, Calvino-Gunther S, Gestin B, Armand-Lefevre L, Leflon V, Chaplain C, Benali A, Francais A, Adrie C, Zahar J-R, Thuong M, Arrault X, Croize J, Lucet J-C; for the Dressing Study Group. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized trial. JAMA 2009; 301(12): 1231-41.

Treggiari MM, Romand J-A, Yanez ND, Deem SA, Jack Goldberg J, Hudson L, Heidegger C-P, Weiss NS. Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med 2009; 37(9): 2527-34.

Barraud D, Blard C, Hein F, Marçon O, Cravoisy A, Nace L, Alla F, Bollaert P-E, Gibot S. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Inten Care Med 2010; 36: 1540-47.

Hajjar LA, Vincent J-L, Galas FRBG, Nakamura RE, Silva CMP, Santos MH, Fukushima J, Filho RK, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Leão WC, Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NAG, Auler Jr JOC. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304(14): 1559-67.

Lacherade J-C, De Jonghe B, Guezennec P, Debbat K, Hayon J, Monsel A, Fangio P, de Vecchi CA, Ramaut C, Outin H, Bastuji-Garin S. Intermittent subglottic secretion drainage and ventilator-associated pneumonia. A multicenter trial. Am J Respir Crit Care Med 2010; 182: 910-7.

Maggiore SM, Richard J-CM, Abroug F, Diehl JL, Antonelli M, Sauder P, Mancebo J, Ferrer M, Lellouche F, Lecourt L, Beduneau G, Brochard L. A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 2010; 38(1): 145-51.

Montejo JC, Miñambres E, Bordejé L, Mesejo A, Acosta J, Heras A, Ferré M, Fernandez-Ortega F, Vaquerizo CI, Manzanedo R. Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. Inten Care Med 2010; 36: 1386-93.

Staudinger T, Bojic A, Holzinger U, Meyer B, Rohwer M, Mallner F, Schellongowski P, Robak O, Laczika K, Frass M, Locker GJ. Continuous lateral rotation therapy to prevent ventilator-associated pneumonia. Crit Care Med 2010; 38(2): 486-90.

Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet 2010; 375: 475-80.

Terragni PP, Antonelli M, Fumagalli R, Faggiano C, Berardino M, Pallavicini FB, Miletto A, Mangione S, Sinardi AU, Pastorelli M, Vivaldi N, Pasetto A, Della Rocca G, Urbino R, Filippini C, Pagano E, Evangelista A, Ciccone G, Mascia L, Ranieri VM. Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA 2010; 303(15): 1483-9.

van Eijk MMJ, Roes KCB, Honing MLH, Kuiper MA, Karakus A, van der Jagt M, Spronk PE, van Gool WA, van der Mast RC, Kesecioglu J, Slooter AJC. Eff ect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 2010; 376: 1829-37.

Andrews PJD, Avenell A, Noble DW, Campbell MK, Croal BL, Simpson WG, Vale LD, Battison CG, Jenkinson DJ, Cook JA; the SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial) Trials Group. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. BMJ 2011; 342: d1542.

PROTECT Investigators for the Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364(14): 1305-14.

Trouillet J-L, Luyt C-E, Guiguet M, Ouattara A, Vaissier E, Makri R, Nieszkowska A, Leprince P, Pavie A, Chastre J, Combes A. Early percutaneous tracheotomy versus prolonged intubation of mechanically ventilated patients after cardiac surgery. A randomized trial. Ann Intern Med 2011; 154(6): 373-383.

Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Greet Van den Berghe G. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365(6): 506-17.

David D, Samuel P, David T, Keshava SN, Irodi A, Peter JV. An open-labelled randomized controlled trial comparing costs and clinical outcomes of open endotracheal suctioning with closed endotracheal suctioning in mechanically ventilated medical intensive care patients. J Crit Care 2011; 26: 482-8.

Ducros L, Logeart D, Vicaut E, Henry P, Plaisance P, Collet J-P, Broche C, Gueye P, Vergne M, Goetgheber D, Pennec P-Y, Belpomme V, Tartière J-M, Lagarde S, Placente M, Fievet M-L, Montalescot G, Payen D; on behalf of the CPAP collaborative study group. CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study. Inten Care Med 2011; 37: 1501-9.

Grau T, Bonet A, Miñambres E, Piñeiro L, Irles JA, Robles A, Acosta J, Herrero I, Palacios V, Lopez J, Blesa A, Martínez P; for the Metabolism, Nutrition Working Group, SEMICYUC, Spain. The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. Crit Care Med 2011; 39(6): 1263-8.

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent J-L, Tortella BJ, Dimsits J, Bouillon B; for the CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69(3): 489-500.

Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E, Zakynthinos E. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011; 39(11): 2440-6.

Rice TW, Mogan S, Hays MA, Bernard GR, Jensen GL, Wheeler AP. Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. Crit Care Med 2011; 39(5): 967-74.

Singer P, Anbar R, Cohen J, Shapiro H, Shalita-Chesner M, Lev S, Grozovski E, Theilla M, Frishman S, Madar Z. The tight calorie control study (TICACOS): a prospective, randomized, controlled pilot study of nutritional support in critically ill patients. Inten Care Med 2011; 37: 601-9.

Takala J, Ruokonen E, Tenhunen JJ, Parviainen I, Jakob SM. Early non-invasive cardiac output monitoring in hemodynamically unstable intensive care patients: a multi-center randomized controlled trial. Crit Care 2011; 15: R148.

Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, Petroni G, Lujan S, Pridgeon J, Barber J, Machamer J, Chaddock K, Celix JM, Cherner M, Hendrix T; for the Global Neurotrauma Research Group. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med 2012; 367(26): 2471-81.

Kwakman PH, Müller MC, Binnekade JM, van den Akker JP, de Borgie CA, Schultz MJ, Zaat SA. Medical-grade honey does not reduce skin colonization at central venous catheter-insertion sites of critically ill patients: a randomized controlled trial. Crit Care 2012; 16: R214.

Mehta S, Burry L, Cook D, Fergusson D, Steinberg M, Granton J, Herridge M, Ferguson N, Devlin J, Tanios M, Dodek P, Fowler R, Burns K, Jacka M, Olafson K, Skrobik Y, Hébert P, Sabri E, Meade M; for the SLEAP Investigators and the Canadian Critical Care Trials Group. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA 2012; 308(19): 1985-92.

Mekontso Dessap A, Roche-Campo F, Kouatchet A, Tomicic V, Beduneau G, Sonneville R, Cabello B, Jaber S, Azoulay E, Castanares-Zapatero D, Devaquet J, Lellouche F, Katsahian S, Brochard L. Natriuretic peptide-driven fluid management during ventilator weaning. A randomized controlled trial. Am J Respir Crit Care Med 2012; 186(12): 1256-63.

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SAR; for the CHEST Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367(20): 1901-11.

Schädler D, Engel C, Elke G, Pulletz S, Haake N, Frerichs I, Zick G, Scholz J, Weiler N. Automatic control of pressure support for ventilator weaning in surgical intensive care patients. Am J Respir Crit Care Med 2012; 185(6): 637-44.

Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, Preiser JC, Outin H, Troché G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Reignier J, Abroug F, Berger P, Clec’h C, Cousson J, Thibault L, Chevret S; for the CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013; 310(17): 1809-17.

Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, Gough K, Vander Hoorn S, Morris ME, Berney S. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months of follow-up. Crit Care 2013; 17: R156.

Doig GS, Simpson F, Sweetman EA, Finfer SR, Cooper DJ, Heighes PT, Davies AR, O’Leary M, Solano T, Peake S; for the Early PN Investigators of the ANZICS Clinical Trials Group. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. JAMA 2013; 309(20): 2130-8.

Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, Thibault R, Pichard C. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet 2013; 381: 385-93.

Hernandez G, Pedrosa A, Ortiz R, Accuaroni MdMC, Cuena R, Collado CV, Plaza SG, Arenas PG, Fernandez R. The effects of increasing effective airway diameter on weaning from mechanical ventilation in tracheostomized patients: a randomized controlled trial. Inten Care Med 2013; 39: 1063-70.

Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; for the Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368(16): 1489-97.

Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013; 369(23): 2197-206.

Papazian L, Roch A, Charles P-E, Penot-Ragon C, Perrin G, Roulier P, Goutorbe P, Lefrant J-Y, Wiramus S, Jung B, Perbet S, Hernu R, Nau A, Baldesi O, Allardet-Servent J, Baumstarck K, Jouve E, Moussa M, Hraiech S, Guervilly C, Forel J-M; for the STATIN-VAP Study Group. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310(16): 1692-1700.

Reignier J, Mercier E, Le Gouge A, Boulain T, Desachy A, Bellec F, Clavel M, Frat J-P, Plantefeve G, Quenot J-P, Lascarrou J-B; for the Clinical Research in Intensive Care and Sepsis (CRICS) Group. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA 2013; 309(3): 249-256.

Vignon P, Dequin P-F, Renault A, Mathonnet A, Paleiron N, Imbert A, Chatellier D, Gissot V, Lhéritier G, Aboyans V, Prat G, Garot D, Boulain T, Diehl J-L, Bressollette L, Delluc A, Lacut K; The Clinical Research in Intensive Care and Sepsis Group (CRICS Group). Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. Inten Care Med 2013; 39: 872-80.

Walsh TS, Boyd JA, Watson D, Hope D, Lewis S, Krishan A, Forbes JF, Ramsay P, Pearse R, Wallis C, Cairns C, Cole S, Wyncoll D; for the RELIEVE Investigators. Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Crit Care Med 2013; 41(10): 2354-63.

Young D, Harrison DA, Cuthbertson BH, Rowan K; for the TracMan Collaborators. Effect of Early vs Late Tracheostomy Placement on Survival in Patients Receiving Mechanical Ventilation: the TracMan randomized trial. JAMA 2013; 309(20): 2121-9.

Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, Purkart TU, Waltensdorfer A, Münch A, Warnkross H, Stojakovic T, Bisping E, Toller W, Smolle K-H, Berghold A, Pieber TR, Dobnig H. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 2014; 312(15): 1520-30.

Boom DT, Sechterberger MK, Rijkenberg S, Kreder S, Bosman RJ, Wester JPJ, van Stijn I, DeVries JH, van der Voort PHJ. Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial. Crit Care 2014; 18: 453.

Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal Checco E, Cariello C, Faita L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabrò MG, Bellomo R, Landoni G. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 2014; 312(21): 2244-53.

Diaz-Prieto A, Mateu A, Gorriz M, Ortiga B, Truchero C, Sampietro N, Ferrer MJ, Mañez R. A randomized clinical trial for the timing of tracheotomy in critically ill patients: factors precluding inclusion in a single center study. Crit Care 2014; 18: 585.

Harvey SE, Parrott F, Harrison DA, Bear DE, Segaran E, Beale R, Bellingan G, Leonard R, Mythen MG, Rowan KM; for the CALORIES Trial Investigators. Trial of the route of early nutritional support in critically ill adults. N Engl J Med 2014; 371(18): 1673-84.

Jüttler E, Unterberg A, Woitzik J, Bösel J, Amiri H, Sakowitz OW, Gondan M, Schiller P, Limprecht R, Luntz S, Schneider H, Pinzer T, Hobohm C, Meixensberger J, Hacke W; for the DESTINY II Investigators. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med 2014; 370(12): 1091-1100.

Kalfon P, Giraudeau B, Ichai C, Guerrini A, Brechot N, Cinotti R, Dequin P-F, Riu-Poulenc B, Montravers P, Annane D, Dupont H, Sorine M, Riou B; on behalf of the CGAO–REA Study Group. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. Inten Care Med 2014; 40: 171-81.

Lellouche F, L’Her E, Abroug F, Deye N, Rodriguez PO, Rabbat A, Jaber S, Fartoukh M, Conti G, Cracco C, Richard JC, Ricard JD, Mal H, Mentec H, Loisel F, Lacherade JC, Taillé S, Brochard L. Impact of the humidification device on intubation rate during noninvasive ventilation with ICU ventilators: results of a multicenter randomized controlled trial. Inten Care Med 2014; 40: 211-9.

Manzano F, Colmenero M, Pérez-Pérez AM, Roldán D, del Mar Jiménez-Quintana M, Mañas MR, Sánchez-Moya MA, Guerrero C, Moral-Marfil MA, Sánchez-Cantalejo E, Fernández-Mondéjar E. Comparison of two repositioning schedules for the prevention of pressure ulcers in patients on mechanical ventilation with alternating pressure air mattresses. Inten Care Med 2014; 40: 1679-87.

Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides, SV; for the PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15): 1402-11.

Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland G, Grocott MPW, Ahern A, Griggs K, Scott R, Hinds C, Rowan K; for the OPTIMISE Study Group. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA 2014; 311(21): 2181-90.

Pérez-Bárcena J, Marsé P, Zabalegui-Pérez A, Corral E, Herrán-Monge R, Gero-Escapa M, Cervera M, Llompart-Pou JA, Ayestarán I, Raurich JM, Oliver A, Buño A, de Lorenzo AG, Frontera G. A randomized trial of intravenous glutamine supplementation in trauma ICU patients. Inten Care Med 2014; 40: 539-47.

Robertson CS, Hannay J, Yamal J-M, Gopinath S, Goodman JC, Tilley BC; the Epo Severe TBI Trial Investigators. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA 2014; 312(1): 36-47.

Schefold JC, von Haehling S, Pschowski R, Bender TO, Berkmann C, Briegel S, Hasper D, Jörres A. The effect of continuous versus intermittent renal replacement therapy on the outcome of critically ill patients with acute renal failure (CONVINT): a prospective randomized controlled trial. Crit Care 2014; 18: R11.

Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes ARJ, ter Wee PM, Groeneveld ABJ; for the CASH study group. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472.

Seguin P, Laviolle B, Dahyot-Fizelier C, Dumont R, Veber B, Gergaud S, Asehnoune K, Mimoz O, Donnio P-Y, Bellissant E, Malledant Y; for the Study of Povidone Iodine to Reduce Pulmonary Infection in Head Trauma and Cerebral Hemorrhage Patients (SPIRIT) ICU Study and AtlanRéa Groups. Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial. Crit Care Med 2014; 42(1): 1-14.

van Zanten ARH, Sztark F, Kaisers UX, Zielmann S, Felbinger TW, Sablotzki AR, De Waele JJ, Timsit J-F, Honing MLH, Keh D, Vincent J-L, Zazzo J-F, Fijn HBM, Petit L, Preiser J-C, van Horssen PJ, Hofman Z. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA 2014; 312(5): 514-24.

Zhou Y, Jin X, Kang Y, Liang G, Liu T, Deng N. Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study. Crit Care 2014; 18: R122.

Andrews PJD, Sinclair HL, Rodriguez A, Harris BA, Battison CG, Rhodes JKJ, Murray GD; for the Eurotherm3235 Trial Collaborators. Hypothermia for intracranial hypertension after traumatic brain injury. N Engl J Med 2015; 373(25): 2403-12.

Arabi YM, Aldawood AS, Haddad SH, Al‑Dorzi HM, Tamim HM, Jones G, Mehta S, McIntyre L, Solaiman O, Sakkijha MH, Sadat M, Afesh L; for the PermiT Trial. Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med 2015; 372(25): 2398-408.

Doig GS, Simpson F, Bellomo R, Heighes PT, Sweetman EA, Chesher D, Pollock C, Davies A, Botha J, Harrigan P, Reade MC. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. Inten Care Med 2015; 41: 1197-208.

Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med 2015; 43(8): 1622-9.

Lacroix J, Hébert PC, Fergusson DA, Tinmouth A, Cook DJ,Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P, Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D;for the ABLE Investigators and the Canadian Critical Care Trials Group. Age of transfused blood in critically ill adults. N Engl J Med 2015; 372(15): 1410-8.

Mesejo A, Montejo-González JC, Vaquerizo-Alonso C, Lobo-Tamer G, Zabarte-Martinez M, Herrero-Meseguer JI, Acosta-Escribano J, Blesa-Malpica A, Martinez-Lozano F. Diabetes-specific enteral nutrition formula in hyperglycemic, mechanically ventilated, critically ill patients: a prospective, open label, blind-randomized, multicenter study. Crit Care 2015; 19: 390.

Mimoz O, Lucet J-C, Kerforne T, Pascal J, Souweine B, Goudet V, Mercat A, Bouadma L, Lasocki S, Alfandari S, Friggeri A, Wallet F, Allou N, Ruckly S, Balayn D, Lepape A, Timsit J-F; for the CLEAN trial investigators. Skin antisepsis with chlorhexidine–alcohol versus povidone iodine–alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet 2015; 386: 2069-77.

Murphy GJ, Pike K, Rogers CA, Wordsworth S, Stokes EA, Angelini GD, Reeves BC; for the TITRe2 Investigators. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015; 372(11): 997-1008.

Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J, Huet O, Mak A, McArthur C, Pettilä V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R; EPO-TBI Investigators and ANZICS Clinical Trials Group. Erythropoietin in traumatic brain injury (EPO-TBI): a double‑blind randomised controlled trial. Lancet 2015; 386(10012): 2499–506.

Souweine B, Lautrette A, Gruson D, Canet E, Klouche K, Argaud L, Bohe J, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Cointault O, Lepape A, Guelon D, Darmon M, Vesin A, Caillot N, Schwebel C, Boyer A, Azoulay E, Bouadma L, Timsit J-F. Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med 2015; 191(9): 1024-32.

Stucker F, Ponte B, Tataw J, Martin P-Y, Wozniak H, Pugin J, Saudan P. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015; 19: 91.

Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum Á, Quantz M, Tagarakis GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S; for the SIRS Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 1243-53.

Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S, Zahn PK, Wolf B, Goebel U, Schwer CI, Rosenberger P, Haeberle H, Görlich D, Kellum JA, Meersch M; for the RenalRIPC Investigators. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 2015; 313(21): 2133-41.

Bandeshe H, Boots R, Dulhunty J, Dunlop R, Holley A, Jarrett P, Gomersall CD, Lipman J, Lo T, O'Donoghue S, Paratz J, Paterson D, Roberts JA, Starr T, Stephens D, Stuart J, Thomas J, Udy A, White H. Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group. J Crit Care 2016; 34: 95–102.

Barbosa EB, Tomasi CD, de Castro Damasio D, Vinhas M, Lichtenfels B, de Luca Francisco V, Fraga CM, Ritter C, Dal‑Pizzol F. Effects of magnesium supplementation on the incidence of acute kidney injury in critically ill patients presenting with hypomagnesemia. Inten Care Med 2016; 42(6): 1084-5.

Demoule A, Clavel M, Rolland‑Debord C, Perbet S, Terzi N, Kouatchet A, Wallet F, Roze H, Vargas F, Guerin C, Dellamonica J, Jaber S, Brochard L, Similowski T. Neurally adjusted ventilatory assist as an alternative to pressure support ventilation in adults: a French multicentre randomized trial. Inten Care Med 2016; 42(11): 1723-32.

Gaudry S, Hajage D, Schortgen F, Martin‑Lefevre L, Pons B, Boulet E, Boyer A, Chevrel G, Lerolle N, Carpentier D, de Prost N, Lautrette A, Bretagnol A, Mayaux J, Nseir S, Megarbane B, Thirion M, Forel J-M, Maizel J, Yonis H, Markowicz P, Thiery G, Tubach F, Ricard J-D, Dreyfuss D; for the AKIKI Study Group. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375(2): 122-33.

Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, Morelli A, Antonelli M, Singer M. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU randomized clinical trial. JAMA 2016; 316(15): 1583-9.

Gobatto ALN, Besen BAMP, Tierno PFGMM, Mendes PV, Cadamuro F, Joelsons D, Melro L, Carmona MJC, Santori G, Pelosi P, Park M, Malbouisson LMS. Ultrasound‑guided percutaneous dilational tracheostomy versus bronchoscopy‑guided percutaneous dilational tracheostomy in critically ill patients (TRACHUS): a randomized noninferiority controlled trial. Inten Care Med 2016; 42(3): 342-51.

Hernández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernández R. Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. JAMA 2016; 315(13): 1354-61.

Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. JAMA 2016; 316(15): 1565-74.

IRONMAN Investigators, Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, Gummer J, Hawkins D, Higgins A, Hofmann A, De Keulenaer B, McMorrow J, Olynyk JK, Richards T, Towler S, Trengove R, Webb S; and The Australian and New Zealand Intensive Care Society Clinical Trials Group. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: a randomized trial of IV iron in critical illness. Inten Care Med 2016; 42(11): 1715-22.

Jaber S, Lescot T, Futier E, Paugam-Burtz C, Seguin P, Ferrandiere M, Lasocki S, Mimoz O, Hengy B, Sannini A, Pottecher J, Abback P-S, Riu B, Belafia F; Constantin J-M, Masseret E, Beaussier M, Verzilli D, De Jong A, Chanques G, Brochard L, Molinari N; NIVAS Study Group. Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a randomized clinical trial. JAMA 2016; 315(13): 1345-53.

Legriel S, Lemiale V, Schenck M, Chelly J, Laurent V, Daviaud F, Srairi M, Hamdi A, Geri G, Rossignol T, Hilly‑Ginoux J, Boisramé‑Helms J, Louart B, Malissin I, Mongardon N, Planquette B, Thirion M, Merceron S, Canet E, Pico F, Tran‑Dinh Y-R, Bedos J-P, Azoulay E, Resche‑Rigon M, Cariou A; HYBERNATUS Study Group. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med 2016; 375(25): 2457-67.

Morris PE, Berry MJ, Files DC, Thompson JC, Hauser J, Flores L, Dhar S, Chmelo E, Lovato J, Case LD, Bakhru RN, Sarwal A, Parry SM, Campbell P, Mote A, Winkelman C, Hite RD, Nicklas B, Chatterjee A, Young MP. Effect of standardized rehabilitation on hospital length of stay among patients with acute respiratory failure: a randomized clinical trial. JAMA 2016; 315(24): 2694-702.

Moss M, Nordon-Craft A, Malone D, Van Pelt D, Frankel SK, Warner ML, Kriekels W, McNulty M, Fairclough DL, Schenkman M. A randomized trial of an intensive physical therapy program for patients with acute respiratory failure. Am J Respir Crit Care Med 2016; 193(10): 1101–10.

Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, Capellier G, Harrigan PWJ, Bailey M; CLOSE Study Investigators and ANZICS Clinical Trials Group. Conservative versus liberal oxygenation targets for mechanically ventilated patients: a pilot multicenter randomized controlled trial. Am J Respir Crit Care Med 2016; 193(1): 43-51.

Schaller SJ, Anstey M, Blobner M, Edrich T, Grabitz SD, Gradwohl-Matis I, Heim M, Houle T, Kurth T, Latronico N, Lee J, Meyer MJ, Peponis T, Talmor D, Velmahos GC, Waak K, Walz JM, Zafonte R, Eikermann M; for the International Early SOMS-guided Mobilization Research Initiative. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet 2016; 388(10052): 1377–88.

Schmid S, Kapfer B, Heim M, Bogdanski R, Anetsberger A, Blobner M, Jungwirth B. Algorithm-guided goal-directed haemodynamic therapy does not improve renal function after major abdominal surgery compared to good standard clinical care: a prospective randomised trial. Crot Care 2016; 20: 50.

Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Abdelhamid YA, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 2016; 44(10): 1842–50.

Swan JT, Ashton CM, Bui LN, Pham VP, Shirkey BA, Blackshear JE, Bersamin JB, Pomer RML, Johnson ML, Magtoto AD, Butler MO, Tran SK, Sanchez LR, Patel JG, Ochoa RA Jr, Hai SA, Denison KI, Graviss EA, Wray NP. Effect of chlorhexidine bathing every other day on prevention of hospital-acquired infections in the surgical ICU: a single-center, randomized controlled trial. Crit Care Med 2016; 44(10): 1822–32.

Zeng J, Wang C-T, Zhang F-S, Qi F, Wang S-F, Ma S, Wu T-J, Tian H, Tian Z-T, Zhang S-L, Qu Y, Liu L-Y, Li Y-Z, Cui S, Zhao H-L, Du Q-S, Ma Z, Li C-H, Li Y, Si M, Chu Y-F, Meng M, Ren H-S, Zhang J-C, Jiang J-J, Ding M, Wang Y-P. Effect of probiotics on the incidence of ventilator‑associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Inten Care Med 2016; 42(6): 1018-28.

Allingstrup MJ, Kondrup J, Wiis J, Claudius C, Pedersen UG, Hein‑Rasmussen R, Bjerregaard MR, Steensen M, Jensen TH, Lange T, Madsen MB, Møller MH, Perner A. Early goal‑directed nutrition versus standard of care in adult intensive care patients: the single‑centre, randomised, outcome assessor‑blinded EAT‑ICU trial. Inten Care Med 2017; 43(11): 1637-47.

Cooper DJ, McQuilten ZK, Nichol A, Ady B, Aubron C, Bailey M, Bellomo R, Gantner D, Irving DO, Kaukonen K-M, McArthur C, Murray L, Pettilä V, French C; TRANSFUSE Investigators and Australian and New Zealand Intensive Care Society Clinical Trials Group. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med 2017; 377(19): 1858-67.

Dubois J, Van Herpe T, van Hooijdonk RT, Wouters R, Coart D, Wouters P, Van Assche A, Veraghtert G, De Moor B, Wauters J, Wilmer A, Schultz MJ, Van den Berghe G, Mesotten D. Software-guided versus nurse-directed blood glucose control in critically ill patients: the LOGIC-2 multicenter randomized controlled clinical trial. Crit Care 2017; 21(1): 212.

Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabrò MG, Grigoryev EV, Likhvantsev VV, Salgado‑Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A; CHEETAH Study Group. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376(21): 2021-31.

Lascarrou JP, Boisrame-Helms J, Bailly A, Le Thuaut A, Kamel T, Mercier E, Ricard J-D, Lemiale V, Colin G, Mira JP, Meziani F, Messika J, Dequin PF, Boulain T, Azoulay E, Champigneulle B, Reignier J; Clinical Research in Intensive Care and Sepsis (CRICS) Group. Video laryngoscopy vs direct laryngoscopy on successful first-pass orotracheal intubation among ICU patients: a randomized clinical trial. JAMA 2017; 317(5): 483-93.

Li Bassi G, Panigada M, Ranzani OT, Zanella A, Berra L, Cressoni M, Parrini V, Kandil H, Salati G, Selvaggi P, Amatu A, Sanz‑Moncosi M, Biagioni E, Tagliaferri F, Furia M, Mercurio G, Costa A, Manca T, Lindau S, Babel J, Cavana M, Chiurazzi C, Marti J-D, Consonni D, Gattinoni L, Pesenti A, Wiener‑Kronish J, Bruschi C, Ballotta A, Salsi P, Livigni S, Iotti G, Fernandez J, Girardis M, Barbagallo M, Moise G, Antonelli M, Caspani ML, Vezzani A, Meybohm P, Gasparovic V, Geat E, Amato M, Niederman M, Kolobow T, Torres A; the Gravity-VAP Network. Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator‑associated pneumonia. Inten Care Med 2017; 43(11): 1572-84.

Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, Soltesz EG, Luber J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, Alexander JH; LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017; 376(21): 2032-42.

Vargas F, Clavel M, Sanchez‑Verlan P, Garnier S, Boyer A, Bui H-N, Clouzeau B, Sazio C, Kerchache A, Guisset O, Benard A, Asselineau J, Gauche B, Gruson D, Silva S, Vignon P, Hilbert G. Intermittent noninvasive ventilation after extubation in patients with chronic respiratory disorders: a multicenter randomized controlled trial (VHYPER). Inten Care Med 2017; 43(11): 1626-36.

Wischmeyer PE, Hasselmann M, Kummerlen C, Kozar R, Kutsogiannis DJ, Karvellas CJ, Besecker B, Evans DK, Preiser J-C, Gramlich L, Jeejeebhoy K, Dhaliwal R, Jiang X, Day AG, Heyland DK. A randomized trial of supplemental parenteral nutrition in underweight and overweight critically ill patients: the TOP-UP pilot trial. Crit Care 2017; 21(1): 142.

Yasuda H, Sanui M, Abe T, Shime N, Komuro T, Hatakeyama J, Matsukubo S, Kawano S, Yamamoto H, Andoh K, Seo R, Inoue K, Noda E, Saito N, Nogami S, Okamoto K, Fuke R, Gushima Y, Kobayashi A, Takebayashi T, Lefor AK; Japanese Society of Education for Physicians and Trainees in Intensive Care (JSEPTIC) Clinical Trial Group. Comparison of the efficacy of three topical antiseptic solutions for the prevention of catheter colonization: a multicenter randomized controlled study. Crit Care 2017; 21(1): 320.

Zhang Q, Li C, Shao F, Zhao L, Wang M, Fang Y. Efficacy and safety of combination therapy of Shenfu injection and postresuscitation bundle in patients with return of spontaneous circulation after in-hospital cardiac arrest: a randomized, assessor-blinded, controlled trial. Crit Care Med 2017; 45(10): 1587–95.

Daubin C, Valette X, Thiollière F, Mira J-P, Hazera P, Annane D, Labbe V, Floccard B, Fournel F, Terzi N, Cheyron DD, Parienti J-J; BPCTrea Study Group. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Inten Care Med 2018; 44(4): 428-37.

Fossat G, Baudin F, Courtes L, Bobet S, Dupont A, Bretagnol A, Benzekri-Lefèvre D, Kamel T, Muller G, Bercault N, Barbier F, Runge I, Nay M-A, Skarzynski M, Mathonnet A, Boulain T. Effect of in-bed leg cycling and electrical stimulation of the quadriceps on global muscle strength in critically ill adults: a randomized clinical trial. JAMA 2018; 320(4): 368-78.

Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, Khan B, Pisani MA, Hyzy RC, Schmidt GA, Schweickert WD, Hite RD, Bowton DL, Masica AL, Thompson JL, Chandrasekhar R, Pun BT, Strength C, Boehm LM, Jackson JC, Pandharipande PP, Brummel NE, Hughes CG, Patel MB, Stollings JL, Bernard GR, Dittus RS, Ely EW; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med 2018; 379(26): 2506-16.

Klarin B, Adolfsson A, Torstensson A, Larsson A. Can probiotics be an alternative to chlorhexidine for oral care in the mechanically ventilated patient? A multicentre, prospective, randomized controlled open trial. Crit Care 2018; 22(1): 272.

Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, Lange T, Rasmussen BS, Siegemund M, Bundgaard H, Elkmann T, Jensen JV, Nielsen RD, Liboriussen L, Bestle MH, Elkjær JM, Palmqvist DF, Bäcklund M, Laake JH, Bådstøløkken PM, Grönlund J, Breum O, Walli A, Winding R, Iversen S, Jarnvig I-L, White JO, Brand B, Madsen MB, Quist L, Thornberg KJ, Møller A, Wiis J, Granholm A, Anthon CT, Meyhoff TS, Hjortrup PB, Aagaard SR, Andreasen JB, Sørensen CA, Haure P, Hauge J, Hollinger A, Scheuzger J, Tuchscherer D, Vuilliomenet T, Takala J, Jakob SM, Vang ML, Pælestik KB, Andersen KLD, van der Horst ICC, Dieperink W, Fjølner J, Kjer CKW, Sølling C, Sølling CG, Karttunen J, Morgan MPG, Sjøbø B, Engstrøm J, Agerholm‑Larsen B, Møller MH; SUP-ICU trial group. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 2018; 379(23): 2199-208.

McWilliams D, Jones C, Atkins G, Hodson J, Whitehouse T, Veenith T, Reeves E, Cooper L, Snelson C. Earlier and enhanced rehabilitation of mechanically ventilated patients incritical care: a feasibility randomised controlled trial. J Crit Care 2018;44: 407-12.

Perkins GD, Mistry D, Gates S, Gao F, Snelson C, Hart N, Camporota L, Varley J, Carle C, Paramasivam E, Hoddell B, McAuley DF, Walsh TS, Blackwood B, Rose L, Lamb SE, Petrou S, Young D, Lall R; Breathe Collaborators. Effect of protocolized weaning with early extubation to noninvasive ventilation vs invasive weaning on time to liberation from mechanical ventilation among patients with respiratory failure: the Breathe randomized clinical trial. JAMA 2018; 320(18): 1881-8.

Writing Group for the PReVENT Investigators. Effect of a low vs intermediate tidal 5 volumes strategy on ventilator-free days in intensive care unit patients without ARDS: a randomized clinical trial. JAMA 2018; 320(18): 1872-80.

Reignier J, Boisramé-Helms J, Brisard L, Lascarrou J-B, Hssain AA, Anguel N, Argaud L, Asehnoune K, Asfar P, Bellec F, Botoc V, Bretagnol A, Bui H-N, Canet E, Da Silva D, Darmon M, Das V, Devaquet J, Djibre M, Ganster F, Garrouste-Orgeas M, Gaudry S, Gontier O, Guérin C, Guidet B, Guitton C, Herbrecht J-E, Lacherade J-C, Letocart P, Martino F, Maxime V, Mercier E, Mira J-P, Nseir S, Piton G, Quenot J-P, Richecoeur J, Rigaud J-P, Robert R, Rolin N, Schwebel C, Sirodot M, Tinturier F, Thévenin D, Giraudeau B, Le Gouge A; the NUTRIREA-2 Trial Investigators and the Clinical Research in Intensive Care and Sepsis (CRICS) group, for the NUTRIREA-2 Trial Investigators and the Clinical Research in Intensive Care and Sepsis (CRICS) group. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet 2018; 391(10116): 133-143.

Ridley EJ, Davies AR, Parke R, Bailey M, McArthur C, Gillanders L, Cooper DJ, McGuinness S; Supplemental Parenteral Nutrition Clinical Investigators. Supplemental parenteral nutrition versus usual care in critically ill adults: a pilot randomized controlled study. Crit Care 2018; 22(1): 12.

Sarfati C, Moore A, Pilorge C, Amaru P, Mendialdua P, Rodet E, Stéphan F, Rezaiguia-Delclaux S. Efficacy of early passive tilting in minimizing ICU-acquired weakness: a randomized controlled trial. J Crit Care 2018; 46: 37-43.

The TARGET Investigators; ANZICS Clinical Trials Group. Energy-dense versus routine enteral nutrition in the critically ill. N Engl J Med 2018; 379(19): 1823-34.

van den Boogaard M, Slooter AJC, Brüggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators. Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial. JAMA 2018; 319(7): 680-690.

van Meenen DMP, van der Hoeven SM, Binnekade JM, de Borgie CAJM, Merkus MP, Bosch FH, Endeman H, Haringman JJ, van der Meer NJM, Moeniralam HS, Slabbekoorn M, Muller MCA, Stilma W, van Silfhout B, Neto AS, ter Haar HFM, Van Vliet J, Wijnhoven JW, Horn J, Juffermans NP, Pelosi P, de Abreu MG, Schultz MJ, Paulus F. Effect of on–demand vs routine nebulization of acetylcysteine with salbutamol on ventilator-free days in intensive care unit patients receiving invasive ventilation: a randomized clinical trial. JAMA 2018; 319(10): 993-1001.

Zhu Y, Yin H, Zhang R, Ye X, Wei J. Gastric versus postpyloric enteral nutrition in elderly patients (age ≥ 75 years) on mechanical ventilation: a single-center randomized trial. Crit Care 2018; 22(1): 170.

**Sepsis**

Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA; the XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266(8): 1097-1102.

Dhainaut J-FA, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet J-P, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira J-P, de Vathaire F, Guinot P; the BN 52021 Study Group. Platelet-activating factor receptor agonist BN 52021 in the treatment of severe sepsis: a randomized double-blind placebo-controlled , multicenter clinical trial. Crit Care Med 1994; 22(11): 1720-8.

Fisher CJ Jr, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC; for the Phase III rhIL-1ra Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271(23): 1836-47.

Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC; for the TNF- MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor  in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273(12): 934-41.

Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RMH. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23(6): 994-1006.

Willatts SM, Radford S, Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med 1995; 23(6): 1033-9.

Cohen J, Carlet, J. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 1996; 24(9): 1431-40.

Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E; for the Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334(26): 1697-702.

Opal SM, Fisher CJ Jr, Dhainaut J-FA, Vincent J-L, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25(7): 1115-24.

Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A; for the Ro 45-2081 Study Group. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA 1997; 277(19): 1531-8.

Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S; for the NORASEPT II Study Group. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33.

Baudo E, Caimi TM, deCataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Inten Care Med 1998; 24: 336-42.

Dhainaut J-FA, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller M-D, Sollet J-P, Wolff M, Holzapfel L, Zeni F, Vedrinne J-M, de Vathaire F, Gourlay M-L, Guinot P, Mira J-P. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1998; 26(12): 1963-71.

Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N; for the E5 Study Investigators. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA 2000; 283(13): 1723-30.

Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11): 2081-9.

Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr; for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. N Engl J Med 2001; 344(10): 699-709.

Angus DC, Laterre P-F, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; for the PROWESS Investigators. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32(11): 2199-206.

Reinhart K, Menges T, Gardlund B, Zwaveling JH, Smithes M, Vincent J-L, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M; the AFELIMOMAB Sepsis Study Group. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 2001; 29(4): 765-9.

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; for the Early Goal-Directed Therapy Collaborative Group. N Engl J Med 2001; 345(19): 1368-77.

Schortgen F, Lacherade J-C, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-6.

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke H-O, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; for the KyberSept Trial Study Group. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286(15): 1869-78.

Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke H-O, Warren BL, Opal SM; for the KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34(2): 285-92.

Annane D, Sébille V, Charpentier C, Bollaert P-E, François B, Korach J-M, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288(7): 1869-78.

Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Inten Care Med 2002; 28: 1434-9.

Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, Schein RM, Macias W, Skerjanec S, Dmitrienko A, Farid N, Forgue T, Jiang F. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31(3): 718-28.

Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; for the OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290(2): 238-47.

Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW; for the MAB-T88 Sepsis Study Group. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with gram-negative sepsis. Crit Care Med 2003; 31(2): 419-27.

Chastre J, Wolff M, Fagon J-Y, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; for the PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290(19): 2588-98.

Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, Boulain T, Lefort Y, Fartoukh M, Baud F, Boyer A, Brochard L, Teboul J-L; for the French Pulmonary Artery Catheter Study Group. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290(20): 2713-20.

Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent J-L, Torres A, Rello J, Nelson S; for the Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31(2): 367-73.

Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J; the Pafase ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31(6): 1612-9.

Opal S, Laterre P-F, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut J-F, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; the Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis (COMPASS) Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32(2): 332-41.

Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; on behalf of the Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32(1): 1-12.

López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32(1): 21-30.

Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C; for the Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32(11): 2173-82.

Reinhart K, Meier-Hellmann A, Beale R, Forst H, Boehm D, Willatts S, Rothe KF, Adolph M, Hoffmann JE, Boehme M, Bredle DL; for the EASy-Study Group. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. Crit Care Med 2004; 32(8): 1662-8.

Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto Á, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353(13): 1332-41.

Laterre P-F, Abraham E, Janes JM, Trzaskoma BL, Correll NL, Booth FV. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Crit Care Med 2007; 35(6): 1457-63.

Lin S-M, Huang C-D, Lin H-C, Liu C-Y,Wang C-H, Kuo H-P. A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 2006; 26(6): 551-7.

Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Übelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006; 34(5): 1319-25.

Pontes-Arruda A, Aragão AFM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006; 34(9): 2325-33.

Angstwurm MWA, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauß R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35(1): 118-26.

Annane D, Vignon P, Renault A, Bollaert P-E, Charpentier C, Martin C, Troché G, Ricard J-D, Nitenberg G, Papazian L, Azoulay E, Bellissant E; for the CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370: 676-84.

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; for the Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-90.

Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues H-H, Verner L, Neumann R, Müller-Werdan U; for the Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007; 35(12): 2693-2701.

Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K; for the German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358(2): 125-39.

Russell JA, Walley KR, Joel Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; for the VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358(9): 877-87.

Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre P-F, Reinhart K, Cuthbertson BH, Payen D, Briegel J; for the CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358(2): 111-24.

Werdan K, Pilz G, Müller-Werdan U, Enriquez MM, Schmitt DV, Mohr F-W, Neeser G, Schöndube F, Schäfers H-J, Haverich A, Fraunberger P, Andersson J, Kreuzer E, Thijs LG; for the Early Supplemental Severe SIRS Treatment With IVIG in Score-Identified High-Risk Patients After Cardiac Surgery (ESSICS) Study Group. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome—The ESSICS study. Crit Care Med 2008; 36(3): 716-23.

Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J; the Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009; 37(11): 2929-38.

Dhainaut J-F, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, Belger M, Cobas-Meyer M, Maier C, Mignini MA, Janes J. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Inten Care Med 2009; 35: 1187-95.

Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13: R159.

Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Muñoz Á. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE study). Crit Care Med 2009; 37(4): 1185-96.

Palizas F, Dubin A, Regueira T, Bruhn A, Knobel E, Lazzeri S, Baredes N, Hernández G. Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial. Crit Care 2009; 13: R44.

Bouadma L, Luyt C-E, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M; for the PRORATA trial group. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-74.

De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent J-L; for the SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362(9): 779-89.

Jansen TC, van Bommel J, Schoonderbeek FJ, Visser SJS, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; for the LACTATE study group. Early lactate-guided therapy in intensive care unit patients. A multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 752-61.

Patel GP, Grahe JS, Sperry M, Singla S, Elpern E, Lateef O, Balk RA. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010; 33(4): 375-80.

Rice TW, Wheeler AP, Bernard GR, Vincent J-L, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Li M, Matsuda H, Mouri K, Cohen J. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38(8): 1685-94.

Tidswell M, Tillis W, LaRosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM; the Eritoran Sepsis Study Group. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38(1): 72-83.

Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM; and the Eritoran Sepsis Study Group. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 2011; 36(4): 327-31.

Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Østergaard C, Kjær J, Grarup J, Lundgren JD; for The Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39(9): 2048-58.

Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB; for the Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT Study. Crit Care 2011; 15: R144.

Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T; for the German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307(22): 2390-9.

Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16: R113.

Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 2012; 16: R94.

Kim JW, Chung J, Choi S-H, Jang HJ, Hong S-B, Lim C-M, Koh Y. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Crit Care 2012; 16: R28.

Perner A, Haase N, Guttormsen AB, Jyrki Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard A-L, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; for the 6S Trial Group and the Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367(2): 124-34.

Perner A, Haase N, Winkel P, Guttormsen AB, Tenhunen J, Klemenzson G, Müller RG, Åneman A, Wetterslev J. Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer’s acetate. Inten Care Med 2014; 40: 927-34.

Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; for the PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366(22): 2055-64.

Schortgen F, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, Dellamonica J, Bouadma L, Cook F, Beji O, Brun-Buisson C, Lemaire F, Brochard L. Fever control using external cooling in septic shock. A randomized controlled trial. Am J Respir Crit Care Med 2012; 185(10): 1088-95.

Trof RJ, Beishuizen A, Cornet AD, de Wit RJ, Girbes ARJ, Groeneveld ABJ. Volume-limited versus pressure-limited hemodynamic management in septic and nonseptic shock. Crit Care Med 2012; 40(4): 1177-85.

Annane D, Timsit J-F, Megarbane B, Martin C, Misset B, Mourvillier B, Siami S, Chagnon J-L, Constantin J-M, Petitpas F, Souweine B, Amathieu R, Forceville X, Charpentier C, Tesnière A, Chastre J, Bohe J, Colin G, Cariou A, Renault A, Brun-Buisson C, Bellissant E; on behalf of the APROCCHSS Trial Investigators. Recombinant human activated protein C for adults with septic shock. A randomized controlled trial. Am J Respir Crit Care Med 2013; 187(10): 1091-7.

Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, Levy M, Lodato RF, Ismail PM, Reese A, Schaumberg JP, Malik R, Dellinger RP; for the TLF LF-0801 Investigator Group. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41(3): 706-16.

Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Gran H, Canivet J-L, Dewitte A, Flamens C, Pujol W, Grandoulier A-S, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Rozé H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Inten Care Med 2013; 39: 1535-46.

Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts MS, Syres G, Venkatesh B; for the ANZ-STATInS Investigators-ANZICS Clinical Trials Group. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187(7): 743-50.

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D’Egidio A, D’Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013; 310(16): 1683-91.

Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang C-S, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent J-L; for the ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309(11): 1154-62.

Vincent J-L, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41(9): 2070-9.

Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Gua X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013; 17: R8.

ARISE Investigators and the ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371(16): 1496-506.

Asfar P, Meziani F, Hamel J-F, Grelon F, Megarbane B, Anguel N, Mira J-P, Dequin P-F, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier J-M, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard J-D, Hervé F, du Cheyron D, Guerin C, Mercat A, Teboul J-L, Radermacher P; for the SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370(17): 1583-93.

Bernard GR, Francois B, Mira J-P, Vincent J-L, Dellinger RP, Russell JA, LaRosa SP, Laterre P-F, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014; 42(3): 504-11.

Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L; for the ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370(15): 1412-21.

Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Åneman A, Vang ML, Winding R, Nebrich L, Nibro HL, Rasmussen BS, Lauridsen JRM, Nielsen JS, Oldner A, Pettilä V, Cronhjort MB, Andersen LH, Pedersen UG, Reiter N, Wiis J, White JO, Russell L, Thornberg KJ, Hjortrup PB, Müller RG, Møller MH, Steensen M, Tjäder I, Kilsand K, Odeberg-Wernerman S, Sjøbø B, Bundgaard H, Thyø MA, Lodahl D, Mærkedahl R, Albeck C, Illum D, Kruse M, Winkel P, Perner A; for the TRISS Trial Group and the Scandinavian Critical Care Trials Group. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014; 371(15): 1381-91.

Rygård SL, Holst LB, Wetterslev J, Winkel P, Johansson PI, Wernerman J, Guttormsen AB, Karlsson S, Perner A; TRISS Trial Group; Scandinavian Critical Care Trials Group. Long‑term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Inten Care Med 2016; 42(11): 1685-94.

Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Inten Care Med 2014; 40: 830-8.

Leone M, Bechis C, Baumstarck K, Lefrant J-Y, Albanèse J, Jaber S, Lepape A, Constantin J-M, Papazian L, Bruder N, Allaouchiche B, Bézulier K, Antonini F, Textoris J, Martin C; for the AZUREA Network Investigators. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Inten Care Med 2014; 40: 1399-408.

ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370(18): 1683-93.

Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, Walker A, Bailey MJ, Johnson B, Millis D, Ding G, Peake S, Wong H, Thomas J, Smith K, Forbes L, Hardie M, Micallef S, Fraser JF; the ProGUARD Study Investigators, and the ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190(10): 1102-10.

Dulhunty JM, Roberts JA, Davis JS,Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J; for the BLING II Investigators for the ANZICS Clinical Trials Group. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015; 192(11): 1298-305.

Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, Coats TJ, Singer M, Young JD, Rowan KM; for the ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 372(14): 1301-11.

Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; The ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Inten Care Med 2015; 41: 975-84.

Vincent J-L, Marshall JC, Dellinger RP, Simonson SG, Guntupalli K, Levy MM, Singer M, Malik R; for the Oral tAlactoferrin in Severe sepsIS Study Investigators. Talactoferrin in severe sepsis: results from the phase II/III Oral tAlactoferrin in Severe sepsIS trial. Crit Care Med 2015; 43(9): 1832-8.

Young P, Saxena M, Bellomo R, Freebairn R, Hammond N, van Haren F, Holliday M, Henderson S, Mackle D, McArthur C, McGuinness S, Myburgh J, Weatherall M, Webb S, Beasley R; for the HEAT Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med 2015; 373(23): 2215-24.

Zhang Z, Ni H, Qian Z. Effectiveness of treatment based on PiCCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome: a randomized controlled trial. Inten Care Med 2015; 41: 444-51.

Abdul-Aziz MH, Sulaiman H, Mat-Nor M-B, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Inten Care Med 2016; 42(10): 1535-45.

Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016; 316(5): 509-18.

Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilä V, Aaen A, Lodahl D, Berthelsen RE, Christensen H, Madsen MB, Winkel P, Wetterslev J, Perner A; The CLASSIC Trial Group, The Scandinavian Critical Care Trials Group. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel‑group, multicentre feasibility trial. Inten Care Med 2016; 42(11): 1695-705.

Hyvernat H, Barel R, Gentilhomme A, Césari-Giordani JF, Freche A, Kaidomar M, Goubaux B, Pradier C, Dellamonica J, Bernardin G. Effects of increasing hydrocortisone to 300 mg per day in the treatment of septic shock: a pilot study. Shock 2016; 46(5): 498-505.

Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn S-O, Hüter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schädler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM; SepNet–Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 316(17): 1775-85.

Timsit J-F, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet J-L, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou J-C, Foucrier A, Allaouchiche B, Das V, Gangneux J-P, Ruckly S, Maubon D, Jullien V, Wolff M; EMPIRICUS Trial Group. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, *Candida* colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA 2016; 316(15): 1555-64.

Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, Meduri GU. Hydrocortisone treatment in early sepsis associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 2016; 20(1): 329

Bergamin FS, Almeida JP, Landoni G, Galas FRBG, Fukushima JT, Fominskiy E, Park CHL, Osawa EA, Diz MPE, Oliveira GQ, Franco RA, Nakamura RE, Almeida EM, Abdala E, Freire MP, Filho RK, Auler JOC Jr, Hajjar LA. Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients randomized controlled trial. Crit Care Med 2017; 45(5): 766-73.

Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, Koami H, Beppu S, Katayama Y, Itoh M, Ohta Y, Yamamura H; Dexmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation (DESIRE) Trial Investigators. Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical trial. JAMA 2017; 317(13): 1321-8.

Limaye AP, Stapleton RD, Peng L, Gunn SR, Kimball LE, Hyzy R, Exline MC, Files DC, Morris PE, Frankel SK, Mikkelsen ME, Hite D, Enfield KB, Steingrub J, O’Brien J, Parsons PE, Cuschieri J, Wunderink RG, Hotchkin DL, Chen YQ, Rubenfeld GD, Boeckh M. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA 2017; 318(8) 731-40.

Madsen MB, Hjortrup PB, Hansen MB, Lange T, Norrby‑Teglund A, Hyldegaard O, Perner A. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo‑controlled trial. Inten Care Med 2017; 43(11): 1585-93.

Rouzé A, Loridant S, Poissy J, Dervaux B, Sendid B, Cornu M, Nseir S; S-TAFE study group. Biomarker‑based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Inten Care Med 2017; 43(11): 1668-77.

Zhou X, Liu D, Su L, Yao B, Long Y, Wang X, Chai W, Cui N, Wang H, Rui X. Use of stepwise lactate kinetics-oriented hemodynamic therapy could improve the clinical outcomes of patients with sepsisassociated hyperlactatemia. Crit Care 2017; 21(1): 33.

Annane D, Renault A, Brun‑Buisson C, Megarbane B, Quenot J-P, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit J-F, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin J-M, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne J-F, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS-TRIGGERSEP Net. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378(9): 809-18.

Barbar SD, Clere‑Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, Lebert C, Bohé J, Badie J, Eraldi J-P, Rigaud J-P, Levy B, Siami S, Louis G, Bouadma L, Constantin J-M, Mercier E, Klouche K, du Cheyron D, Piton G, Annane D, Jaber S, van der Linden T, Blasco G, Mira J-P, Schwebel C, Chimot L, Guiot P, Nay M-A, Meziani F, Helms J, Roger C, Louart B, Trusson R, Dargent A, Binquet C, Quenot J-P; IDEAL-ICU Trial Investigators; CRICS TRIGGERSEP Network. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis.

Dellinger RF, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 2018; 320(14): 1455-63.

Philippe Montravers1,18\* , Florence Tubach2, Thomas Lescot3, Benoit Veber4, Marina Esposito‑Farèse5,

Seguin P, Paugam C, Lepape A, Meistelman C, Cousson J, Tesniere A, Plantefeve G, Blasco G, Asehnoune K, Jaber S, Lasocki S, Dupont H; DURAPOP Trial Group. Short‑course antibiotic therapy for critically ill patients treated for postoperative intra‑abdominal infection: the DURAPOP randomised clinical trial. Inten Care Med 2018; 44(3): 300-10.

Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J; ADRENAL Trial Investigators; Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018; 378(9): 797-808.

Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, Vincent J-L, Werdan K, Martin‑Loeches I, Almirall J, Artigas A, Ayestarán JI, Nuding S, Ferrer R, Rodríguez GS, Shankar‑Hari M, Álvarez‑Lerma F, Riessen R, Sirvent J-P, Kluge S, Zacharowski K, Mora JB, Lapp H, Wöbker G, Achtzehn U, Brealey D, Kempa A, García MS, Brederlau J, Kochanek M, Reschreiter HP, Wise MP, Belohradsky BH, Bobenhausen I, Dälken B, Dubovy P, Langohr P, Mayer M, Schüttrumpf J, Wartenberg‑Demand A, Wippermann U, Wolf D, Torres A. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community‑acquired pneumonia: a randomized, placebo‑controlled, double‑blind, multicenter, phase II trial (CIGMA study). Inten Care Med 2018; 44(4): 438-48.

**ARDS**

Anzuete A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventós AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN; for the Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334(22): 1417-21.

Brochard L, Roudot-Thoraval F, Roupie E, Delclaux C, Chastre J, Fernandez-Mondéjar E, Clémenti E, Mancebo J, Factor P, Matamis D, Ranieri M, Blanch L, Rodi G, Mentec H, Dreyfuss D, Ferrer M, Brun-Buisson C, Tobin M, Lemaire F; The Multicenter Trial Group on Tidal Volume Reduction in ARDS. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158: 1831-8.

Stewart TE, Meade MO, Cook DJ, Granton JT, Hodder RV, Lapinsky SE, Mazer CD, McLean RF, Rogovein TS, Shouten BD, Todd TRJ, Slutsky AS; The Pressure- and Volume-Limited Ventilation Strategy Group. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. N Engl J Med 1998; 338(6): 355-61.

Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C; for the European Study Group of Inhaled Nitric Oxide. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Inten Care Med 1999; 25: 911-9.

ARDS Network Authors for the ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000; 283(15): 1995-2002.

The Acute Respiratory Distress Syndrome Netwoork. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1301-8.

Delclaux C, L’Her E, Alberti C, Mancebo J, Abroug F, Conti G, Guérin C, Schortgen F, Lefort Y, Antonelli M, Lepage E, Lemaire F, Brochard L. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: a randomized controlled trial. JAMA 2000; 284(18): 2352-60.

Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, Brazzi L, Latini R; for the Prone-Supine Study Group. N Engl J Med 2001; 345(8): 568-73.

The ARDS Clinical Trials Network; National Heart, Lung, and Blood Institute; National Institutes of Health. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30(1): 1-6.

Schoenfeld D. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. Crit Care 2006;10: 103.

Derdak S, Mehta S, Stewart TE, Smith T, Rogers M, Buchman TG, Carlin B, Lowson S, Granton J; and the Multicenter Oscillatory Ventilation for Acute Respiratory Distress Syndrome Trial (MOAT) Study Investigators. High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults. A randomized, controlled trial. Am J Respir Crit Care Med 2002; 166: 801-8.

Fernández-Vivas M, Caturla-Such J, de la Rosa JG, Acosta-Escribano J, Álvarez-Sánchez B, Cánovas-Robles J. Noninvasive pressure support versus proportional assist ventilation in acute respiratory failure. Inten Care Med 2003; 29: 1126-33.

Ferrer M, Esquinas A, Leon M, Gonzalez G, Alarcon A, Torres A. Noninvasive ventilation in severe hypoxemic respiratory failure. A randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438-44.

The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351(4): 327-36.

Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard R, Beuret P, Palmier B, Le QV, Sirodot M, Rosselli S, Cadiergue V, Sainty J-M, Barbe P, Combourieu E, Debatty D, Rouffineau J, Ezingeard E, Millet O, Guelon D, Rodriguez L, Martin O, Renault A, Sibille J-P, Kaidomar M. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 2004; 292(19): 2379-87.

Zeiher BG, Artigas A, Vincent J-L, Dmitrienko A, Jackson K, Thompson BT, Bernard G; for the STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004; 32(8): 1695-702.

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354(24): 2564-75.

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354(21): 2213-24.

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354(16): 1671-84.

Kacmarek RM, Wiedemann HP, Lavin PT, Wedel MK, Tütüncü AS, Slutsky AS. Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173: 882-9.

Mancebo J, Fernández R, Blanch L, Rialp G, Gordo F, Ferrer M, Rodríguez F, Garro P, Ricart P, Vallverdú I , Gich I, Castaño J, Saura P, Domínguez G, Bonet A, Albert RK. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173: 1233-9.

Villar J, Kacmarek RM, Pérez-Méndez L, Aguirre-Jaime A; for the ARIES Network. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. Crit Care Med 2006; 34(5): 1311-8.

Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE; for the Lung Open Ventilation Study Investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008; 299(6): 637-45.

Mercat A, Richard J-CM, Vielle B, Jaber S, Osman D, Diehl J-L, Lefrant J-Y, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L, for the Expiratory Pressure (Express) Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008; 299(6): 646-55.

Morris PE, Papadakos P, Russell JA, Wunderink R, Schuster DP, Truwit JD, Vincent J-L, Bernard GR. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med 2008; 36(3): 782-8.

Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby J-J, Holzapfel L, Bruins P, Steenken EJ, Jeppesen OK, Lachmann B. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009; 180: 989-94.

Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D; for the CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351-63.

Taccone P, Pesenti A, Latini R, Polli F, Vagginelli F, Mietto C, Caspani L, Raimondi F, Bordone G, Iapichino G, Mancebo J, Guérin C, Ayzac L, Blanch L, Fumagalli R, Tognoni G, Gattinoni L; for the Prone-Supine II Study Group. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 2009; 302(18): 1977-84.

Vincent J-L, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 2009; 37(6): 1874-80.

Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, Renard B, Tonnelier J-M, Blot F, Chevret S, Schlemmer B. Diagnostic strategy for hematology and oncology patients with acute respiratory failure. Randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 1038-46.

Determann RM, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F, Hofstra J-J, de Graaff MJ, Korevaar JC, Schultz MJ. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. Crit Care 2010; 14: R1.

Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal J-M, Perez D, Seghboyan J-M, Constantin J-M, Courant P, Lefrant J-Y, Guérin C, Prat G, Morange S, Roch A; for the ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363(12): 1107-16.

Spragg RG, Taut FJH, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Günther A. Recombinant surfactant protein C–based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011; 183: 1055-61.

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184: 561-8.

Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P; for the NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, γ-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306(14): 1574-81.

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA 2012; 307(8): 795-803.

Needham DM, Dinglas VD, Bienvenu OJ, Colantuoni E, Wozniak AW, Rice TW, Hopkins, RO; for the NIH NHLBI ARDS Network. One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ 2013; 346: f1532.

Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, Khan Z, Lamb SE; for the BALTI-2 study investigators. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379: 229-35.

Paine III R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40(1): 90-7.

Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q, Matte A, Walter SD, Lamontagne F, Granton JT, Arabi YM, Arroliga AC, Stewart TE, Slutsky AS, Meade MO; for the OSCILLATE Trial Investigators and the Canadian Critical Care Trials Group. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med 2013; 368(9): 795-805.

Guérin C, Reignier J, Richard J-C, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; for the PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368(23): 2159-68.

Young D, Lamb SE, Shah S, MacKenzie I, Tunnicliffe W, Lall R, Rowan K, Cuthbertson BH; for the OSCAR Study Group. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med 2013; 368(9): 806-13.

The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370(23): 2191-200.

McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, McNally C, and the HARP-2 Investigators; for the Irish Critical Care Trials Group. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014; 371(18): 1695-703.

Agus A, Hulme C, Verghis RM, McDowell C, Jackson C, O’Kane CM, Laffey JG, McAuley DF. Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial. Crir Care 2017; 21(1): 108.

Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, Nyunga M, Girault C, Perez P, Guitton C, Ekpe K, Kouatchet A, Théodose I, Benoit D, Canet E, Barbier F, Rabbat A, Bruneel F, Vincent F, Klouche K, Loay K, Mariotte E, Bouadma L, Moreau A-S, Seguin A, Meert A-P, Reignier J, Papazian L, Mehzari I, Cohen Y, Schenck M, Hamidfar R, Darmon M, Demoule A, Chevret S, Azoulay E; for the Groupe de Recherche en Réanimation Respiratoire du patient d’Onco-Hématologie (GRRR-OH). Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 2015; 314(16): 1711-9.

Willson DF, Truwit JD, Conaway MR, Traul CS, Egan EE. The adult calfactant in acute respiratory distress syndrome trial. Chest 2015; 148(2): 356-64.

Kacmarek RM, Villar J, Sulemanji D, Montiel R, Carlos Ferrando C, Blanco J, Koh Y, Alfonso Soler JA, Martínez D, Hernández M, Tucci M, Borges JB, Lubillo S, Santos A, Araujo JB, Amato MBP, Suárez-Sipmann F; the Open Lung Approach Network. Open lung approach for the acute respiratory distress syndrome: a pilot, randomized controlled trial. Crit Care Med 2016; 44(1): 32-42.

Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2017;318(14):1335-1345.

Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pène F, Kontar L, Bruneel F, Klouche K, Barbier F, Reignier J, Berrahil-Meksen L, Louis G, Constantin J-M, Mayaux J, Wallet F, Kouatchet A, Peigne V, Théodose I, Perez P, Girault C, Jaber S, Oziel J, Nyunga M, Terzi N, Bouadma L, Lebert C, Lautrette A, Bigé N, Raphalen J-H, Papazian L, Darmon M, Chevret S, Demoule A. Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial. JAMA 2018; 320(20): 2099-2107.

Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A; for the EOLIA Trial Group, REVA, and ECMONet. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018; 378(21): 1965-75.

**Supplemental Table 2 Interventions Shown to Improve Survival in ICU-based Clinical Trials**

|  |  |
| --- | --- |
| **Study Population** | **Intervention** |
| **Sepsis**  **ARDS/Acute Lung Injury**  **Other** | ***Pharmacologic agents***  Acetaminophen, activated protein C, antibody to tumor necrosis factor, corticosteroidsa, esmolol,  intravenous immunoglobulin, platelet-activating factor acetylhydrolase, selenium, talactoferrin, thymosin-α, tissue factor pathway inhibitor  ***Resuscitation and Support***  Early goal-directed therapy a,f, external cooling, immunonutrition, lactate-guided resuscitationa, norepinephrine vs dopaminea, plasmapheresis, transfusion in septic shock  ***Ventilatory Support***  Extracorporeal membrane oxygenation, non-invasive ventilation b, neuromuscular blockade a, prone positioninga, reduced tidal volume, PEEPa  Addition of EDTA to propofol c  Citrate anticoagulation for CVVH e  Colloid resuscitation  Early tracheostomy  Erythropoietin for traumatic brain injury  Gastric tonometry  Hemicraniectomy for MCA stroke d  Immunonutrition  Intensive insulin therapy a,f  Invasive diagnosis of pneumonia  Passive tilting  Pravastatin  Progesterone for traumatic brain injury  Reduced oxygen threshold target  Sedation interruption a  Selective digestive tract decontamination  Shenfu for cardiac arrest  Surveillance for sinusitis  Vitamin D3 |

1. Recommended or suggested in the 2017 guidelines of the Surviving Sepsis Campaign (1)
2. Recommended in the European Respiratory Society guidelines for non-invasive ventilation (2)
3. Incorporated into formulation of propofol <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019627s066lbl.pdf>
4. Recommended in the American Heart Association/American Stroke Association guidelines for the management of cerebral infarction (3)
5. Recommended in the KDIGO Clinical Practice Guidelines for Acute Kidney Injury (4)
6. Initial results contradicted by findings of subsequent multicenter RCT (1)